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Obesity is a major public health concern, both in the United States and 
worldwide. Therefore, identification of measures by which obesity may be 
prevented and reversed is of high priority. Epidemiological studies consistently 
demonstrate an inverse relationship between serum 25(OH)D levels, an indicator 
of vitamin D status, and measures of adiposity. These data suggest that vitamin 
D may play a role in the prevention of excessive adiposity. However, whether 
vitamin D impacts lipid storage and metabolism in terminally differentiated 
adipocytes is not yet known. The purpose of this work was to determine the 
impact of 1,25-dihydroxyvitamin D (1,25(OH)2D), the bioactive vitamin D 
metabolite, on triacylglycerol accumulation and lipid and glucose metabolism in 
differentiated adipocytes. To study this, 3T3-L1 adipocytes were differentiated for 
9 days, followed by stimulation with 1,25(OH)2D (10 nM) or vehicle for 1-7 days. 
Results indicate that 1,25(OH)2D stimulates a 21% reduction in TAG 
accumulation in differentiated 3T3-L1 adipocytes after 4 days (P=0.01). This 
occurs despite a significant increase in fatty acid uptake (P<0.01), assessed 
using BODIPY FL C16, and with concomitant stimulation of PKA-dependent 
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glycerol release (P<0.01), which is typically indicative of lipolysis. Additionally, we 
demonstrate that 1,25(OH)2D stimulates a 2.5-fold increase in complete fatty acid 
oxidation (P<0.01), assessed by quantifying the production of 14CO2 from [1-14C] 
palmitic acid. These results suggest a novel mechanism by which 1,25(OH)2D 
may be protective against excessive adiposity. In addition to its impact on fatty 
acid metabolism, the impact of 1,25(OH)2D on glucose metabolism was also 
examined. Glucose contributes significantly to the intracellular TAG pool, serving 
as a substrate for both fatty acid synthesis as well as glycerol production to 
support TAG synthesis. The results indicate that 1,25(OH)2D reduces the 
incorporation of D-[U-13C]glucose incorporation into palmitic, palmitoleic, stearic, 
and oleic acids (P=0.03), determined by liquid chromatography-mass 
spectrometry (LC-MS). Interestingly, [13C2]acetate incorporation into these fatty 
acids was reduced by only 10% (p<0.01), suggesting that while de 
novo lipogenesis is slightly inhibited in response to 1,25(OH)2D, the contribution 
of glucose specifically as a substrate for fatty acid synthesis is reduced. Study of 
glucose uptake and disposal as lactate revealed that these two processes are 
not impacted by 1,25(OH)2D, suggesting that glucose may instead be used for 
the synthesis of glycerol. Indeed, inhibition of glycolysis to reduce substrate 
availability for glycerol synthesis completely prevented 1,25(OH)2D-stimulation of 
glycerol release. These data suggest that rather than stimulating TAG hydrolysis, 
1,25(OH)2D stimulates disposal of glucose as glycerol, while reducing its 
utilization as a substrate for fatty acid synthesis. While the mRNA expression of 
pyruvate carboxylase (PC) is reduced by 40% in response to 1,25(OH)2D 
xiv 
 
(P<0.01), suggesting that 1,25(OH)2D may limit pyruvate entry into the TCA 
cycle, at this time it is not clear whether this underlies the 1,25(OH)2D-stimulated 
changes in glucose metabolism and TAG storage. In conclusion, 1,25(OH)2D 
stimulates fatty acid oxidation in 3T3-L1 adipocytes, and reduces the contribution 
of glucose to the fatty acid pool, likely by stimulating glucose disposal as glycerol. 
These results demonstrate that 1,25(OH)2D regulates both fatty acid and glucose 
metabolism in differentiated 3T3-L1 adipocytes to reduce TAG storage. These 
novel findings demonstrate a mechanism by with 1,25(OH)2D may protect 
against excessive fat mass accumulation, and provide support for the inverse 
relationship between vitamin D and obesity.
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CHAPTER 1. LITERATURE REVIEW 
1.1 Obesity and Associated Metabolic Disorders 
Obesity has become a major public health concern, with over 36% of 
adults and 17% of children and adolescents in the United States considered 
obese (1). Individuals who are obese are at increased risk for developing chronic 
diseases and metabolic disorders, as well as certain types of cancer (2).  
Additionally, it is estimated that medical costs associated with obesity account for 
over 20% of all annual health care spending in the United States, and that direct 
and indirect costs from obesity exceed $275 billion annually (3). Because of 
these devastating physical, psychological, and financial costs of obesity, it is 
imperative that effective measures to prevent and reverse obesity are identified. 
Several measures exist by which individuals may be classified according 
to their weight status and associated disease risk. Body mass index (BMI) is a 
quick and inexpensive method of weight assessment, and is positively correlated 
with metabolic disorders that are associated with obesity. Therefore, BMI is often 
used as a screening tool for categorizing individuals by weight. Body mass index 
is calculated by dividing an individual’s weight in kilograms by the square of 
height in meters. While BMI is not a direct measure of adiposity, BMI does 
correlate with direct measures of body fat, including dual energy x-ray 
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absorptiometry (DEXA), bioelectrical impedance, densitometry, and skinfold 
thickness measurements (4, 5). For adults 20 years and older, BMI is used to 
categorize individuals as underweight (BMI < 18.5), normal weight (BMI 18.5-
24.9), overweight (BMI 25.0-29.9), or obese (BMI >30.0) (2). Epidemiological 
data show a modest increased risk of mortality when BMI reaches above 25 
kg/m2 (6-8), and a 50-100% risk of all-cause mortality when BMI reaches 30 
kg/m2 (7, 8). 
While BMI serves as a convenient and inexpensive measure of weight 
assessment, it does not distinguish between excessive adipose and muscle 
mass, and is therefore not diagnostic individual of health risk (9). A more 
accurate representation of an individual’s health risk may be obtained by 
assessing percent body fat. The “gold standard” for measuring body fat is DEXA, 
but this method is expensive and not always accessible. Estimates of percent 
body fat may also be obtained using handheld or scale instruments that measure 
bioimpedance, or by measurements of skinfold (10). To avoid elevated weight-
associated health risks, the recommended body fat percentage ranges for men 
and women are 12-20% and 20-30%, respectively (11).  
There are many diseases and health conditions associated with obesity. 
Individuals who are obese are more likely than lean individuals to experience 
sleep apnea, depression, anxiety, and osteoarthritis (2, 12, 13).  Further, 
metabolic disorders such as hypertension, dyslipidemia, coronary artery disease, 
and type 2 diabetes are more prevalent among those who are obese, as are 
certain types of cancer such as that of the breast, colon, kidney, gallbladder, and 
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liver (2, 14).  Adipose tissue dysfunction often underlies obesity-associated 
metabolic disorders, and modulation of adipose tissue metabolism has become a 
target for combating obesity and associated chronic diseases. 
1.1.1 Adipose Tissue Physiology 
1.1.1.1 Characteristics of Adipose Tissue 
For the vast majority of individuals, adipose tissue is the largest energy 
reservoir in the body (15). In animals, approximately one-third of the cells found 
in adipose tissue are adipocytes, while the remaining two-thirds are a 
combination of fibroblasts, preadipocytes, stem cells, as well as nerve tissue and 
vasculature (16). Historically, adipose tissue was considered to be an organ 
devoted mainly to energy storage and thermal regulation, while serving as a 
source of cushioning to protect internal organs (17). However, the complexity of 
this tissue has been identified in recent years, and it is now known that functions 
of adipose tissue also include regulation of appetite, insulin sensitivity and 
glucose homeostasis, lipid metabolism, inflammation and immunity, as well as 
angiogenesis and blood pressure (17, 18).  
In humans, adipose tissue is organized in discrete anatomical depots: 
subcutaneous and visceral.  Adipose tissue ranges from 5-60% of total body 
mass, with subcutaneous adipose tissue (SAT) accounting for 80% or more of 
the total fat mass (19). The subcutaneous adipose tissue lies under the skin and 
includes abdominal, gluteal, and femoral adipose depots (19). Accumulation of 
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subcutaneous fat mass, or peripheral obesity, is thought to be protective against 
metabolic disease (20-26).  
On the other hand, visceral adipose tissue (VAT) is associated with 
digestive organs, and represents 10-20% of the total fat mass in men, and 5-10% 
of that in women. Visceral adipose depots include the omental, which associates 
with the stomach, the intestine-associated mesenteric, and the epiploic, which 
can be found along the colon (19).  Excessive accumulation of visceral adipose 
tissue, termed “central obesity,” is associated with risk of metabolic disorders 
(20-24, 26). It is thought that VAT confers elevated risk of metabolic disorders 
because of its direct access to the portal vein; hepatocytes are exposed to high 
levels of fatty acids freed by lipolysis from VAT, which may lead to hepatic insulin 
resistance, hepatic glucose production and fasting hyperglycemia (27). Further, 
production of proinflammatory cytokines has been found to be higher in VAT than 
in SAT depots (28), contributing to the increased metabolic disease risk with 
excessive VAT accumulation. 
1.1.1.2 Functions of Adipose Tissue 
One of the longest-known functions of adipose tissue is maintenance of 
energy homeostasis. Adipocytes can store excess energy in cytoplasmic lipid 
droplets, in the form of triacylglycerol (TAG). Postprandially, or in response to 
overnutrition, this function prevents ectopic lipid deposition in tissues such as the 
liver, heart, and skeletal muscle, and prevents lipotoxicity in these organs (29). 
Conversely, during fasting, or when energy demand exceeds energy intake, TAG 
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stores may be hydrolyzed to release fatty acids from the cell for use by other 
tissues. The storage and hydrolysis of TAG in adipocytes prevents excess 
circulating energy substrates when food is plentiful, and ensures constant energy 
availability during prolonged periods of fasting (30).  
While adipose tissue was originally considered an inert energy storage 
reservoir that also provides temperature and mechanical insulation, adipose 
tissue has recently  recognized as an active endocrine organ (31). Adipose tissue 
secretes a variety of bioactive peptides, called adipokines, which participate in 
the regulation of feeding behavior, glucose and lipid metabolism, energy 
homeostasis, immunity, inflammation, adipogenesis and vascular function (32). 
Adipokines secreted by adipose tissue include adiponectin, leptin, resistin, 
adipsin, and visfatin, as well as cytokines such as IL-6 and TNFα. These factors 
that are secreted by adipocytes act locally, peripherally, and centrally to impact 
tissue metabolism and cross-talk (15). 
1.1.1.3 Adipocyte Biology 
While adipocytes account for approximately one-third of the cells found in 
adipose tissue, adipocytes constitute approximately 90% of the total tissue 
volume due to their large size. Three distinct types of adipocytes exist: white, 
brown, and beige. Phenotypically, white adipocytes are large, round, and 
unilocular (i.e. they contain one large lipid droplet).  White adipocytes do not 
express uncoupling protein-1 (UCP-1), and they have a low mitochondrial 
density. Their main functions are to act as an energy reservoir and as an 
6 
 
endocrine organ. Brown adipocytes are multilocular, exhibit high levels of UCP-1 
expression, and have a high mitochondrial density, which confers their brown 
color. Brown adipocytes also function as a source of thermogenesis. Beige, or 
brite, adipocytes exhibit characteristics that are intermediate to brown and white 
adipocytes. Beige adipocytes exhibit UCP-1 expression, and have multiple lipid 
droplets. The major functions and characteristics of these different types of 
adipocytes are still under investigation (33).  
1.1.1.3.1 White Adipocytes 
 The white adipocyte is the most abundant type of adipocyte in the adipose 
tissue. Its major functions are to store and release fuel during times of energy 
excess and deprivation, and to contribute to the endocrine functions of adipose 
tissue. Lipogenesis and lipolysis within the adipocyte are regulated in the short 
term by hormonal signals in circulation. However, long-term maintenance of 
adipose tissue and changes in energy storage require changes in both size and 
number of adipocytes. An increase in cell number, or hyperplasia, is achieved by 
stimulating the differentiation of preadipocytes, which are also found in adipose 
tissue. 
Much of what is known about adipocyte differentiation was determined 
using the murine 3T3-L1 preadipocyte cell line. This cell line is one of the most 
common, and best characterized, models used to investigate adipocyte 
development and function. When injected into mice, 3T3-L1 preadipocytes 
differentiate and form fat pads that are indistinguishable from the mouse adipose 
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tissue (34). Differentiation of 3T3-L1 post-confluent preadipocytes can be 
achieved using a differentiation cocktail consisting of insulin, a glucocorticoid, an 
agent that stimulates intracellular cyclic AMP (cAMP) formation, and fetal bovine 
serum (35). Typically, a cocktail of insulin, dexamethasone (DEX), a synthetic 
glucocorticoid agonist, and isomethylbutylxanthine (IBMX), a phosphodiesterase 
inhibitor used to stimulate intracellular cAMP accumulation, is used to stimulate 
adipogenesis in 3T3-L1 adipocytes (36).  
Preadipocyte differentiation occurs following a temporal cascade of 
transcriptional events (Figure 1.1) (37). Cell-to-cell contact at confluence 
stimulates the expression of lipoprotein lipase (LPL) and type IV collagen, early 
markers of adipocyte differentiation (38, 39). Within one hour after addition of the 
differentiation cocktail, transient expression (lasting 2-6 hours) of c-fos, c-jun, and 
c-myc is observed, as well as the expression of CCAAT/enhancer binding protein 
(C/EBP) β and δ (40). Within 24 hours after administration of the differentiation 
cocktail, postconfluent mitosis and subsequent growth arrest occur, after which 
cells are committed to becoming adipocytes (41). Upon removal of the 
differentiation cocktail, expression of C/EBPβ and δ dissipate within 2-8 days 
(42). However, their transient expression and activity are needed for the 
expression of peroxisome proliferator-activated receptor γ (PPARγ) (43, 44) and 
C/EBPα (45, 46), which are induced 2 days after initiation of differentiation and 
are maximally expressed by 3-5 days following initiation of differentiation. The 
sustained expression of both PPARγ and C/EBPα are necessary for the 













Figure 1.1. Adipocyte differentiation transcriptional cascade.  C/EBP: CCAAT-
enhancer-binding protein; DEX: dexamethasone; IBMX: 3-isobutyl-1-
methylxanthine. Adapted from “Adipocyte differentiation and gene expression,” 
by Ntambi JM and Young-Cheul K., The Journal of Nutrition 2000; 130: 3122S-
3126S. Adapted with permission from the American Society for Nutrition. 
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lipid and glucose metabolism, and for development of the mature adipocyte 
phenotype (47). 
1.1.1.3.2 Brown Adipocytes 
 There are many characteristics that distinguish brown from white 
adipocytes, namely, high mitochondrial density, UCP-1 expression, and the 
presence of many small lipid droplets (33). The high levels of mitochondrial UCP-
1 expression in brown adipocytes cause uncoupling of the mitochondrial 
respiratory chain from ATP production, allowing energy to dissipate as heat by a 
process called non-shivering thermogenesis (48). This process is stimulated in 
response to β-adrenergic receptor stimulation, such as that which occurs when 
noradrenaline is released upon cold exposure (49, 50). In mice, brown 
adipocytes are found in inter-scapular, sub-scapular, and cervical regions (51). 
While originally thought to be only present in infant humans, recent studies 
employing 18F-fluorodeoxyglucose (FDG) positron emission 
tomography/computed tomography (PET-CT) analysis of glucose uptake have 
identified BAT in adult humans (52). Further, it has been demonstrated that the 
abundance of BAT is inversely correlated with BMI and total adipose mass, 
highlighting the therapeutic potential of targeting BAT to combat obesity (52-57). 
Several studies suggest independent lineages for the developmental origins of 
white and brown adipocytes; specifically, that brown adipocytes share a common 
lineage with myogenic cells (58-62). However, the origins of brown and white 
adipocytes remain incompletely understood, and whether selectively increasing 
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BAT mass and/or activity in humans is achievable, in order to combat obesity, is 
under current investigation (33).  
1.1.1.3.3 Beige Adipocytes 
  A third type of adipocyte is the beige, or “brite” (brown-in-white) adipocyte. 
These adipocytes resemble brown adipocytes in that they express UCP-1, are 
multilocular, and have higher mitochondrial density than white adipocytes (63, 
64). Under basal conditions, beige adipocytes exhibit a phenotype similar to 
white adipocytes. However, in response to cold stimulation, these adipocytes are 
“browned,” and display characteristics similar to the brown adipocyte (33). While 
the primary function of beige adipocytes appears to be thermogenesis, the 
characterization of this cell type is under investigation. 
1.1.1.4 Adipocyte Lipid Metabolism 
 Fatty acids serve a variety of functions within all cells, including as an 
energy source, as a precursor for cellular membranes, and as precursors for 
signaling molecules. In adipocytes, fatty acids are also stored in the form of TAG, 
so that during times of energy deficit they may be released for use by other 
tissues. As such, the adipocyte must maintain tight regulation over the processes 
used to take up, synthesize, store, and release fatty acids.  
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1.1.1.4.1 Fatty Acid Uptake 
 Fatty acids can be taken up as free fatty acids (FFA), which circulate 
bound to serum albumin, or can be obtained through the hydrolysis of TAG, 
which are carried in circulation by lipoproteins such as chylomicrons or very low-
density lipoproteins (VLDL). Postprandially, or after a meal, fatty acids obtained 
from the diet are packaged by enterocytes into chylomicrons, which first enter 
circulation within the lymphatic system, followed by entry into the bloodstream.  
These chylomicrons, along with very low density lipoproteins (VLDL) secreted by 
the liver, transport fatty acids in the form of TAG to peripheral tissues such as 
adipose tissue, skeletal muscle, and the heart. Chylomicrons and VLDLs are 
spherical particles featuring a hydrophobic lipid core containing neutral lipids 
such as TAG, cholesterol esters, and sterol esters, surrounded by a polar lipid 
surface layer that contains phospholipids and free cholesterol, as well as 
apolipoproteins that collectively provide a hydrophilic interface with the aqueous 
surroundings in circulation (65, 66). 
 Chylomicrons and VLDL are relatively large in size, having diameters of 
100-1200 nm and 30-80 nm, respectively (66). In order to enter the cell, TAG 
must be hydrolyzed to fatty acids intravascularly by lipoprotein lipase (LPL). 
Intravascular lipolysis removes up to 90% of TAG from the circulating lipoprotein, 
allowing fatty acids to be taken up by peripheral tissues. The apolipoprotein 
remnant is taken up by hepatocytes, for use in VLDL synthesis (67). 
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Uptake of fatty acids by cells can occur by several mechanisms (68). 
While long chain fatty acids may diffuse passively across phospholipid bilayers 
(69), a variety of facilitated transport mechanisms by integral or membrane-
associated proteins have been identified (70). To enter the cell, the fatty acid 
must first dissociate from the lipoprotein or serum albumin, diffuse through the 
outer aqueous phase and insert into the outer plasma membrane, translocate or 
“flip-flop” from the outer to the inner plasma membrane, and dissociate from the 
inner membrane to the aqueous cytosolic phase of the cell (71). Proteins at the 
plasma membrane such as fatty acid transport protein (FATP), fatty acid binding 
protein (FABP), caveolin-1, and CD36 have been implicated in the uptake and 
utilization of fatty acids (68, 71). However, the precise mechanisms of FA 
transport across cell membranes, and the relative contributions of diffusion- and 
protein-mediated uptake, remain a source of interest and controversy (71, 72).  
1.1.1.4.2 Fatty Acid Synthesis 
 In addition to the uptake of exogenous fatty acids, the adipocyte may 
synthesize fatty acids de novo from non-lipid precursors such as glucose (Figure 
1.2). The key transcription factor regulating expression of genes involved in 
lipogenesis is sterol regulatory element-binding protein-1c (SREBP-1c), and the 
primary enzymes involved in fatty acid synthesis are fatty acid synthase (FAS) 
and acetyl-CoA carboxylase (ACC) (73). When glucose is abundant, increased 
flux through glycolysis leads to excess citrate in the tricarboxylic acid (TCA) 








Figure 1.2. Summary of fatty acid and triacylglycerol synthesis in adipocytes. 
ACC: acetyl-CoA carboxylase; ACL: ATP-citrate lyase; AGPAT: 1-acylglycerol-3-
phosphate acyltransferase; DGAT: diacylglycerol acyltransferase; FAS: fatty acid 
synthase; GPAT: glycerol-3-phosphate acyltransferase; GPDH: glycerol-3-
phosphate dehydrogenase; MDH: malate dehydrogenase; ME: malic enzyme; 
OAA: oxaloacetate; PC: pyruvate carboxylase; PDH; pyruvate dehydrogenase; 







fatty acid synthesis (74). Cytosolic acetyl-CoA is carboxylated by ACC to form 
malonyl-CoA. Malonyl-CoA joined to acetyl-CoA by FAS, and this hydrocarbon 
chain is elongated to form palmitic acid, which may then be further elongated or 
desaturated, and esterified with G3P to form TAG (15). In humans, de novo 
lipogenesis accounts for approximately 20% of newly formed TAG-palmitate (75), 
highlighting the significance of adipose tissue DNL contribution to total fat mass 
stores. 
1.1.1.4.3 Triacylglycerol Synthesis 
Whether obtained from circulation or synthesized de novo, intracellular 
fatty acids are esterified to glycerol-3-phosphate (G3P) for storage in lipid 
droplets as TAG. In lipogenic tissues such as adipose tissue and the liver, 
glycerol-3-phosphate may be derived from three sources: glycolysis, 
glyceroneogenesis, and glycerol kinase activity (76). During glycolysis, glucose 
that has been taken up into the cell is phosphorylated and through a series of 
reactions converted to G3P and dihydroxyacetone phosphate (DHAP). The 
DHAP may be converted to G3P by glycerol phosphate dehydrogenase (GPDH) 
to form G3P, which may then be used for TAG synthesis. In humans, 
approximately 20-25% of glucose taken up by adipocytes following an overnight 
fast is used for G3P synthesis and incorporation into TAG (77). 
Alternatively, G3P may be synthesized from non-glucose precursors such 
as pyruvate, lactate, and amino acids by a process called glyceroneogenesis. 
Pyruvate is carboxylated to oxaloacetate (OAA), which then exits the 
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mitochondria and is decarboxylated by cytoplasmic phosphoenolpyruvate 
carboxykinase (PEPCK) to form phosphoenolpyruvate (PEP), the rate-limiting 
step of glyceroneogenesis (78). Phosphoenolpyruvate is then converted 
glyceraldehyde-3-phosphate followed by DHAP, which can then be converted to 
G3P by GPDH. While hepatocytes may use glycerol secreted by adipose during 
lipolysis for G3P and TAG synthesis, the activity of glycerol kinase, which 
phosphorylates glycerol to G3P, is negligible in adipose tissue, and 
glyceroneogenesis is quantitatively the largest contributor of adipocyte G3P 
synthesis (79). 
In adipocytes, TAG is synthesized by esterification of alcoholic residues of 
G3P by a series of enzymes including glycerol-3-phosphate acyltransferase 
(GPAT), 1-acylglycerol-3-phosphate acyltransferase (AGPAT), phosphatidic acid 
phosphatase, and diacylglycerol acyltransferase (DGAT), found on the smooth 
endoplasmic reticulum (15). TAG that is synthesized in adipocytes is stored in 
cytosolic lipids droplets. In humans, de novo lipogenesis may account for up to 
40% of whole-body lipogenesis (80). 
1.1.1.4.4 Lipolysis 
 When energy demand exceeds energy intake, adipose TAG maybe 
hydrolyzed by a process called lipolysis, so that fatty acids and glycerol moieties 
may be utilized by other tissues (66) (Figure 1.3). The initial step of TAG 
hydrolysis is catalyzed by adipose triglyceride lipase (ATGL) (81). ATGL activity 









Figure 1.3. Summary of adipocyte lipolysis. AC: adenylate cyclase; ATGL: 
adipocyte triglyceride lipase 1; AQP7: aquaglyceroporin 7; CGI-58: comparative 
gene identification-58; HSL: hormone sensitive lipase; IRS-1: insulin receptor 
substrate-1; MAGL: monoacylglycerol lipase; PDE: phosphodiesterase E; PDK: 




and by activation by cofactor comparative gene identification-58 (CGI-58) (85). In 
the basal state, CGI-58 is associated with perilipin on the surface of the lipid 
droplet. In response to a lipolytic stimulus, such as β-adrenergic stimulation by a 
catecholamine, perilipin is phosphorylated by protein kinase A (PKA). This 
stimulates the dissociation of CGI-58 from perilipin, and its translocation to 
ATGL, stimulating ATGL hydrolase activity (86, 87). ATGL is rate-limiting for TAG 
hydrolysis (66). 
 Activation of PKA also results in the phosphorylation of hormone-sensitive 
lipase (HSL), the rate-limiting enzyme for diacylglycerol (DAG) hydrolysis (88). In 
addition to DAG, HSL can also hydrolyze fatty acids from TAG, monoacylglycerol 
(MAG), and cholesterol esters (66), and phosphorylation of HSL at serine 660 
(Ser660) regulates HSL enzymatic activity (89). The monocylglycerol that is 
produced by the combined activities of ATGL and HSL is hydrolyzed to glycerol 
and free fatty acid by the enzyme monoglyceride lipase (MGL). MGL is 
expressed ubiquitously, with highest levels of expression found in adipose tissue 
and the kidney (66). 
 Hormone-stimulated lipolysis occurs when a hormone such as a 
catecholamine binds to the G-protein-coupled β-adrenergic receptor. This 
stimulates adenylate cyclase to produce cyclic-AMP (cAMP), the accumulation of 
which activates PKA. PKA phosphorylates perilipin and HSL, and these two 
phosphorylation events stimulate the translocation of CGI-58 from perilipin to 
ATGL, and the activation and translocation of cytoplasmic HSL to the lipid 
droplet, respectively. These phosphorylation and translocation events trigger the 
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complete hydrolysis of TAG to three fatty acids and free glycerol. The fatty acids 
freed by lipolysis can exit the cell to be used by other tissues, or a portion of 
them may be oxidized through a process called β-oxidation in the adipocyte (66). 
A small amount of fatty acids hydrolyzed in response to hormone-stimulated 
lipolysis, approximately 10-20%, are reesterified as TAG (73, 90-92). 
 In addition to hormone-stimulated lipolysis, adipocytes also undergo basal 
lipolysis. In this state, 30-100% of fatty acids hydrolyzed from the lipid droplet are 
reesterified in situ as TAG in a process termed futile TAG/FA cycling (73, 90-92). 
This TAG/FA cycling is essential for buffering plasma fatty acid levels and 
maintaining tight control over opposing metabolic fluxes (93). This cycling also 
plays a role in the synthesis of lipolytic signaling molecules, e.g. fatty acids and 
diacylglycerols (73).  
1.1.1.4.5 Fatty Acid Oxidation  
 While the oxidation of fatty acids, or β-oxidation, has been most 
extensively studied in oxidative tissue such as skeletal muscle and the liver, β-
oxidation plays a significant role in white adipocyte metabolism (74). During 
differentiation, adipocytes exhibit increased expression of mitochondrial 
biogenesis marker PGC1α, and increased mitochondrial oxidative capacity (73). 
Prior to entry into the mitochondria for oxidation, fatty acids are activated to form 
fatty acyl-CoAs. Following activation, these fatty acyl-CoAs, and are then 
transported through the outer mitochondrial membrane by carnitine palmitoyl 
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transferase-1 (CPT-1). This transport of fatty acyl-CoAs across the mitochondrial 
membrane byCPT-1 is the rate-limiting step of β-oxidation.  
The coordinate regulation of lipolysis, β-oxidation, and TAG synthesis are 
modulated hormonally, in response to food intake and thus substrate availability 
(74). The purpose of lipolysis is to provide energy in the form of fatty acids, for 
adipose and other tissues. As glucose is the preferred energy substrate of these 
tissues, there is no need for lipolysis or β-oxidation when glucose is present. 
Insulin, released from the pancreas in response to feeding, blunts lipolysis in 
adipose tissue through Akt-mediated phosphorylation of phosphodiesterase 3B 
(PDE3B) (94). Activation of PDE3B reduces the intracellular cAMP pool, and 
consequently, PKA-mediated activation of ATGL and HSL. Additionally, indirect 
suppression of lipolysis occurs in response to insulin-stimulated glucose uptake 
and flux through glycolysis. Adipocytes dispose of a portion of glucose as lactate 
(95, 96). Once lactate exits the cell, it can bind to the G protein-coupled GPR81 
receptor to inhibit cAMP synthesis, and downstream lipolytic signaling via an 
autocrine lactate loop (97). In the presence of glucose, the cytosolic acetyl-CoA 
pool that is derived from TCA cycle intermediates is converted to malonyl-CoA by 
ACC during de novo lipogenesis. ACC activity is regulated via phosphorylation by 
cellular energy sensory AMPK. Malonyl-CoA is a potent inhibitor of CPT-1, and 
prevents β-oxidation in a lipogenic state (74). Conversely, when cellular energy 
demands exceed substrate availability, AMPK-stimulation of cAMP synthesis by 




1.1.1.5 Glucose Metabolism 
 While skeletal muscle is considered the primary “sink” for glucose 
disposal, adipose tissue plays a critical role in regulating glucose homeostasis 
(98). A study by Abel et al. demonstrated that relative to control mice, those with 
adipose-specific ablation of the GLUT4 glucose transporter exhibit reduced 
glucose utilization in adipose tissue and glucose intolerance, as well as impaired 
insulin signaling in the liver and skeletal mice (99). Further, glucose homeostasis 
in mice lacking GLUT4 in skeletal muscle can be restored by overexpressing 
GLUT4 in adipose tissue (100). This beneficial effect of adipose glucose disposal 
is dependent on the ability of adipose tissue to utilize glucose for the synthesis of 
fatty acids (101).  
 Glucose may be taken up into the adipocyte via glucose transporter type 1 
(GLUT), under basal conditions, or via the GLUT4 glucose transporter in 
response to insulin stimulation after a meal (102). While GLUT1 is constitutively 
expressed on the plasma membrane of adipocytes, insulin-stimulated GLUT4 is 
considered the predominant glucose transporter in adipocytes (74). Under basal 
conditions, GLUT4 is stored in small intracellular vesicles (103). In response to 
insulin, the PI3K-Akt signaling cascade is triggered, stimulation the exocytosis of 
GLUT4-containing vesicles to the cell membrane, and within minutes increasing 
flux of glucose into the cell 10- to 30-fold (103, 104). 
 Once inside the cell, glucose is utilized in multiple cell processes. In 
addition to serving as a source of ATP, glucose also serves as a substrate for the 
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synthesis of fatty acids. Additionally, as adipocytes are unable to recycle glycerol 
freed by lipolysis, glucose also serves as a substrate for G3P synthesis. It is 
estimated that 20-25% of glucose consumed by adipocytes is used for synthesis 
of TAG (77).  
1.1.2 Changes in Adipose Tissue During Obesity 
In a lean individual, adipose tissue works with other tissues to maintain 
normal metabolic, inflammatory, and vascular function. In response to 
overnutrition, the adipocyte can store excess energy in lipid droplets by 
esterifying fatty acids, obtained directly from the diet or synthesized de novo from 
glucose, into triacylglycerol. This partitioning of excess energy into adipose tissue 
prevent ectopic lipid deposition and lipotoxicity in organs such as the liver, heart, 
and skeletal muscle, and preserves normal metabolic functioning in these tissues 
(29). However, during the development of obesity, several changes occur in 
adipose tissue that disrupt normal functioning.  
In response to chronic overnutrition, adipose tissue must expand in order 
to accommodate the increased need for energy storage. To do so, the adipose 
tissue must increase in cell number, by a process called hyperplasia, or in cell 
size, by a process called hypertrophy (74). While both of these processes 
contribute to the maintenance of body fat mass, a study by Spalding et al. 
demonstrate that changes in cell size, rather than in cell number, underlie 
changes in adipose mass during weight loss or gain (105). In this study, it was 
found that adipocytes exhibit an annual turnover rate of 10%, regardless of age 
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and body mass index. Enlargement of adipocytes stimulates changes in 
adipocyte metabolism and secretory profile, and this adipocyte dysfunction plays 
a central role in the development of obesity-associated comorbidities, including 
insulin resistance, type 2 diabetes, and cardiovascular disease (32). 
The expansion of adipose mass triggers a series of inflammatory events. 
As the adipocyte expands, a state of hypoxia develops as interstitial oxygen 
tension decreases within the adipose tissue (106, 107). This stimulates 
stabilization of HIF1α, which is rapidly degraded under normoxic conditions, and 
upregulation of genes containing HIF1α response elements, such as those 
required for angiogenesis (108).  In lean individuals, macrophages found in 
adipose tissue express markers of the M2, or alternatively activated, state. M2 
macrophages are characterized by secretion of anti-inflammatory cytokines, such 
as interleukin-10 (IL-10) (31). During obesity, recruitment and accumulation of 
M1, or classically activated, macrophages occurs. M1 macrophages 
characterized by increased production of pro-inflammatory cytokines tumor 
necrosis factor alpha (TNFα) and interleukin-6 (IL-6), which promote insulin 
resistance and low-grade systemic inflammation (18, 31).  
As the white adipose tissue further expands, necrosis occurs, stimulating 
the development of “crown-like structures” composed of the dead adipocyte 
surrounded by macrophages (109). The rate of cell death is positively correlated 
with adipocyte size in mice and in humans, and is increased up to 30-fold in 
obese compared to lean individuals (110). This inflammatory response is 
implicated in the metabolic disturbances associated with obesity.  
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In addition to elevated local and systemic inflammation, dysregulation of 
lipolysis occurs during the development of obesity (111). In obese and insulin-
resistant individuals, catecholamine-induced lipolysis is blunted in subcutaneous 
adipose tissue, but increased in visceral adipose depots (112, 113). Further, 
basal (unstimulated) lipolysis is increased in obese compared to individuals (112, 
114), and this uncontrolled release of fatty acids is closely associated with 
obesity-associated insulin resistance, independent of age or BMI (115). These 
obesity-induced metabolic consequences have a devastating impact on overall 
health and quality of life. The need to identify safe, effective measures by which 
the burden of obesity can be prevented and reversed is critical. This dissertation 
discusses the potential impact of vitamin D on obesity and obesity-associated 
metabolic disorders. 
1.2 Role of Vitamin D in Human Health  
1.2.1 Sources of Vitamin D 
Vitamin D is a 9, 10 secosteroid that was first discovered by Dr. E.V. 
McCollum in 1922 as the factor present in cod liver oil that cured rickets in 
experimental beagles (116). Of the many forms of vitamin D that have been 
identified, only vitamins D2 (ergocalciferol; fungal origin) and D3 (cholecalciferol; 
animal origin) (Figure 1.4) are relevant to human health (117). Vitamin D3 is a 
biologically inert prohormone made endogenously from 7-dehydrocholesterol in 













Figure 1.4. Chemical structures of vitamins D2 and D3. 
 















7-dehydrocholesterol is converted to pre-vitamin D3 which is then converted to 
vitamin D3 upon the temperature-sensitive rearrangement of three double bonds 
(119). Modest amounts of vitamin D3 may also be obtained in the diet through 
consumption of vitamin D-fortified dairy products and fatty fish. While reports of 
superiority of vitamin D3 have been made when supplemented at high doses 
(120), at low doses, vitamins D2 and D3 are nutritionally equivalent (121). 
1.2.1.1 Vitamin D Metabolism 
 Whether obtained through the diet or synthesized endogenously, vitamin 
D circulates in the blood bound to vitamin D binding protein (DBP).  While vitamin 
D itself does not have biological activity, it becomes active upon hydroxylation at 
two distinct sites. In the liver, vitamin D is hydroxylated C-25 by the 25-
hydroxylase CYP2R1 to produce 25-hydroxyvitamin D (25(OH)D).  25-
hydroxylation in the liver is not a highly regulated step (122), and serum 
concentrations of 25(OH)D are a universally accepted biomarker of vitamin D 
status (123-125).   
Though 25(OH)D is the major circulating metabolite of vitamin D, 
conversion to the active metabolite 1,25-dihydroxyvitamin D (1α,25(OH)2D; 
calcitriol) requires an additional hydroxylation at C-1, which occurs in the kidney. 
When DBP-bound 25(OH)D reaches the kidney, it is filtered by the glomerulus. 
Megalin, a transmembrane protein found in tubular epithelial cells, acts as a cell 
surface receptor for DPB, and catalyzes the uptake of 25(OH)D by endocytic 
internalization (126). In the proximal renal tubule, conversion of 25(OH)D to 
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1α,25(OH)2D is mediated by the renal 1α-hydroxylase CYP27B1.  This enzyme is 
under tight regulation in the kidney; it is activated by serum PTH and suppressed 
by 1,25(OH)2D, calcium and phosphorus (127, 128). While the kidney is the main 
site of 25(OH)D activation under periods of low calcium or low phosphorus 
stress, CYP27B1 expression and 1α-hydroxylase activity have now been 
identified in several extra-renal tissues, including skin, colon, lung, bone, 
prostate, intestine, pancreatic islets, vasculature, liver, brain, muscle and adipose 
tissue (129-131).  The extra-renal 1α-hydroxylase is not regulated by PTH (132, 
133), suggesting that elevated 25(OH)D status may lead to local production of 
1α,25(OH)2D independent of calcium status to yield autocrine and paracrine 
responses. In response to elevated circulating 1,25(OH)2D levels, the renal 
CYP27B1 hydroxylates 1,25(OH)2D, and also 25(OH)2D, at C-24 to signal for its 
degradation and excretion (134, 135). While concentrations vary widely based on 
dietary intake, studies have demonstrated that both vitamin D and 25(OH)D may 
be found in adipose tissue, skeletal muscle and liver, though the largest pool of 
25(OH)D is found in serum (125, 136).  
1.2.1.2 Classical Signaling of 1,25(OH)2D through the Vitamin D Receptor 
Like other steroid hormones, 1,25(OH)2D functions through a nuclear 
receptor, in this case, the vitamin D receptor (VDR).  The VDR belongs to the 
class II of steroid receptors, and is closely related to the thyroid hormone and 
retinoic acid receptors (128, 137), and is evolutionarily conserved among 
mammals, birds, and fish (138). Like other nuclear receptors, the VDR has a 
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ligand-binding domain called the E-domain, a DNA-binding domain called the C-
domain, and an activating domain called the F-domain (116). The human VDR 
protein contains 427 amino acids, and acts by binding to vitamin D response 
elements (VDREs), which are typically found within 1 kilobase of the transcription 
start site of the vitamin D target gene. The VDREs are repeat sequences of 6 
nucleotides separated by 3 nonspecific bases (116).  
Upon entry into the cell, 1,25(OH)2D binds to the VDR, causing a 
conformational change in the VDR that allows it to interact and form a 
heterodimer with the retinoid X receptor (RXR).  This heterodimer binds to the 
VDRE to regulate transcription of vitamin D target genes (139). Binding of the 
VDR-RXR heterodimer to VDREs stimulates recruitment of transcriptional 
coactivators such as p160 coactivator and steroid receptor activator (SRC) (119). 
Once this complex forms, transcription is either stimulated or repressed, 
depending on the gene (116). 1,25(OH)2D regulation of transcriptional events 
through the VDR is responsible for the regulation of calcium homeostasis (137, 
140). In addition to its identification in tissues controlling calcium homeostasis, 
the VDR has now been identified in virtually all other tissues (141-143), as well 
as a variety of cancer cells including those from the breast, colon, and prostate 
(144-147).  This broad distribution of VDR supports the existence of extraskeletal 
effects for 1,25(OH)2D (139, 148, 149).  
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1.2.1.3 Rapid Signaling through the Membrane Vitamin D Receptor  
 Though the most well-established mechanisms of calcitriol action are through the 
nuclear VDR to modulate gene expression, strong evidence exists proving non-
genomic actions of 1,25(OH)2D as well.  First documentation of rapid 1,25(OH)2D 
action was in a 1984 study by Nemere (150), in which addition of 120 pM 
1,25(OH)2D to perfused deuodena of normal, vitamin D-replete chicks resulted in 
a significant increase of 45Ca transport from the lumen to the vascular effluent 
within 14 minutes.  This rapid response, within minutes, contrasts with genomic 
responses which may take hours to several days, and can be blocked by 
inhibitors of transcription and translation.  Since this discovery, many studies 
have emerged supporting the existence of non-genomic actions of calcitriol in 
regulation of calcium transport in several cell types, including hepatocytes, the 
promyelocytic HC-60 cell line, renal tissue and mammary glands, among others 
(151). 
 Investigation of the mechanisms of 1,25(OH)2D-stimulation of rapid 
signaling events have revealed a novel role for the vitamin D receptor.  Many 
ligand structure-function studies have been done to elucidate rapid responses of 
1,25(OH)2D bound to the classic VDR, including rapid stimulation of: calcium 
absorption in chick enterocytes (152, 153), insulin secretion from rat pancreatic β 
cells (89), rate of human endothelial cell migration (154), and MAPK and 
PI3K/Akt signaling cascades to regulate proliferation and differentiation in 
skeletal muscle (155-157). In these studies, the 1α,25(OH)2D agonist could be 
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inhibited by the rapid response antagonist 1β,25(OH)2D, but not by the genomic 
response antagonist (23S)-25-dehydro-1α-OH-D3-26,23-lactone (158).  Further, 
these rapid responses were also induced by 6-s-cis locked 1α,25(OH)2-
lumisterol, which binds to the VDR (153). Together, these data demonstrate that 
the rapid responses initiated by 1,25(OH)2D do in fact occur through the classical 
VDR, but also that rapid responses require a different ligand structure (6-s-cis) 
than that required for a 1,25(OH)2D-induced genomic response (6-s-trans) (159).  
1.2.1.4 A Non-VDR Membrane-Associated Binding Protein is Involved in Rapid 
1,25(OH)2D Signaling 
 Though there are a data to support a direct role for the VDR in non-
genomic 1,25(OH)2D actions, initial studies in enterocytes, chondrocytes, and 
osteoblasts suggested that a different 1,25(OH)2D binding protein controlled rapid 
calcitriol-induced signal transduction pathways.  Indirect evidence for a putative 
membrane receptor for 1,25(OH)2D was obtained during the initial discovery of 
calcitriol rapid signaling in the intestine.  In these studies, treatment of the 
basolateral membrane with exogenous 1,25(OH)2D rapidly enhanced calcium 
transport, whereas exposure of the brush border failed to have this effect (150).  
This suggested that 1,25(OH)2D receptor exists on the basolateral membrane.   
Isolation and full characterization and identification of this basolateral 
membrane receptor in chick intestinal epithelial cells was achieved several years 
later, and was termed the 1,25(OH)2D-membrane-associated, rapid-response 
steroid-binding (MARRS) protein (160).  The transcript for the 1,25(OH)2D-
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MARRS includes a 5’-unstranslated region, a signal peptide, no transmembrane 
domain and two thioredoxin motifs.  Analysis of the cloned chicken cDNA for the 
1,25(OH)2D-MARRS revealed that it is identical to the multifunctional protein 
ERp57 protein (also called p57/GRp58/Pdia3).  The ERp57 is a thiol:protein 
disulphide oxidoreductase, and is a member of the protein disulfide isomerase 
(PDI) family (161). First identified as a luminal chaperone protein of the 
endoplasmic reticulum to facilitate oxidative folding of glycoproteins, ERp57 
exists also in the cytoplasm and nucleus, and functions as a scaffolding protein 
on the cell surface (162).  
 1,25(OH)2D-MARRS mediates several 1,25(OH)2D-induced effects in 
various cell types, including rapid (seconds to minutes) phosphate (163, 164) and 
calcium (165, 166) uptake in intestinal epithelial cells and perfused duodena, 
modulation of growth inhibitory activity of 1,25(OH)2D in breast cancer cells 
(167), regulation of growth plate physiology in chondrocytes and matrix vesicle 
models (168), and initiation of 1,25(OH)2D signaling pathways in osteoblast 
differentiation (169).   
1.2.1.5 Classical Roles of Vitamin D in Calcium Metabolism and Bone Health 
Historically, the chief functions of vitamin D are those related to bone 
mineralization (170).  It is well established that the rachitic skeleton can be 
mineralized by infusion of calcium and phosphorus to raise their serum levels into 
normal ranges (171), indicating that a direct role for vitamin D in bone 
mineralization is not likely.  However, vitamin D does contribute to bone health by 
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maintaining serum calcium and phosphorus concentrations within ranges 
necessary to support bone mineralization.  The control of serum calcium occurs 
through events occurring at a three-tissue axis of bone, intestine, and kidney.  
When dietary calcium is insufficient, vitamin D is converted to its hormonal form 
1,25(OH)2D, that acts on the enterocyte to activate active transport of calcium 
and also phosphorus, on the osteoclast to mediate bone resorption, and on the 
kidney to increase renal reabsorption of calcium in the distal tubule.  All of these 
events contribute to maintaining plasma calcium concentrations within a very 
narrow range (116, 123).   
1.2.1.6 Extraskeletal Functions of Vitamin D 
In addition to those related to maintaining serum calcium and bone 
mineralization, several extraskeletal functions of vitamin D have been identified. 
Meta-analysis of randomized clinical trials have demonstrated that vitamin D 
status is inversely correlated with cancer-related mortality, suggesting that 
vitamin D may act to inhibit the progression of certain cancers (119). In particular, 
evidence exists demonstrating vitamin D inhibition of prostate, breast, and colon 
cancer progression. Additionally, observational studies demonstrate an inverse 
relationship between vitamin D status and risk of cardiovascular disease, and in 
vitro studies have demonstrated 1,25(OH)2D regulation of cell proliferation and 
differentiation, as well as regulation of immune function (119, 172). 
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1.2.1.7 Recommendations for Dietary Intake of Vitamin D 
Current recommendations for serum 25(OH)D are made based on the 
impact that vitamin D has on skeletal health (173) (Table 1.1). Serum 25(OH)D 
levels of 50 nmol/L (20 ng/mL) are considered adequate to normalize bone and 
calcium metabolism in at least 97.5% of the population.  The Institute of Medicine 
(IOM) defines “insufficiency” as any serum 25(OH)D concentration < 50 nmol/L, 
and “deficiency” as levels of serum 25(OH)D levels at which bone health is 
compromised, i.e. <30 nmol/L (12 ng/mL) (173). The Recommended Dietary 
Allowances (RDAs) for vitamin D, the average daily level of intake sufficient to 
meet vitamin D requirements of 97%-98% of healthy individuals, are listed in 
Table 1.2 (121).  
While rare, it is possible to achieve vitamin D toxicity, particularly with 
long-term use of extreme vitamin D supplementation. Symptoms of vitamin D 
toxicity include anorexia leading to weight loss, heart arrhythmias, and polyuria. 
In more serious cases, vitamin D toxicity may lead to elevated blood calcium 
levels, resulting in vascular and tissue calcification, and consequently, cardiac, 
renal, and vascular damage (121). The occurrence of vitamin D toxicity is rare,  
however, and it is not possible to achieve toxicity from foods or sunlight exposure 
(124).The Tolerable Upper Intake Levels (ULs) for vitamin D, or the highest 
average daily intake level likely to pose no risk of adverse health outcomes, are 

















nmol/L* ng/mL Health Outcome 
<30 <12 
Vitamin D deficiency, leading to rickets and 
osteomalacia in children and adults 
30 to <50 12 to <20 
Generally considered adequate for bone 
health in healthy individuals 
≥50 ≥20 
Generally considered adequate for bone 
health in healthy individuals 
>125 >50 
Risk of adverse effects is increased when 
serum 25(OH)D reaches >125 nmol/L 




















Age Male Female Pregnancy Lactation 
0-12 months* 400 IU 400 IU     
  (10 µg) (10 µg)     
1-13 years 600 IU 600 IU     
  (15 µg) (15 µg)     
14-18 years 600 IU 600 IU 600 IU 600 IU 
  (15 µg) (15 µg) (15 µg) (15 µg) 
19-50 years 600 IU 600 IU 600 IU 600 IU 
  (15 µg) (15 µg) (15 µg) (15 µg) 
51-70 years 600 IU 600 IU     
  (15 µg) (15 µg)     
>70 years 800 IU 800 IU     
  (20 µg) (20 µg)     














Age Male Female Pregnancy Lactation 
0-6 months 1,000 IU 1,000 IU     
  (25 µg) (25 µg)     
7-12 months 1,500 IU 1,500 IU     
  (38 µg) (38 µg)     
1-3 years 2,500 IU 2,500 IU     
  (63 µg) (63 µg)     
4-8 years 3,000 IU 3,000 IU     
  (75 µg) (75 µg)     
≥9 years 4,000 IU 4,000 IU 4,000 IU 4,000 IU 
  (100 µg) (100 µg) (100 µg) (100 µg) 
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However, the above described definitions of vitamin D adequacy, 
insufficiency, and deficiency are not universally used, and some strongly oppose 
these current IOM recommendations (174).  Recent evidence from some studies 
evaluating thresholds for serum 25(OH)D concentrations in relation to bone as 
well as several extraskeletal endpoints suggest that the most advantageous 
serum 25(OH)D concentrations begin at 75 nmol/L (30 ng/mL), and are optimal 
between 90 and 100 nmol/L (36-40 ng/mL) (175). Whether there is sufficient 
evidence to conclude that optimal serum 25(OH)D levels are higher than current 
IOM  levels remains a matter of debate. 
The prevalence of vitamin D deficiency is widespread, both in the U.S. 
(176) and worldwide (177). It is estimated that approximately one-third of the 
U.S. population is vitamin D deficient or insufficient, with certain ethnic groups at 
particularly high risk of low vitamin D status, including non-Hispanic blacks 
(>70%) and Hispanics/Mexicans (>40%) (178). This raises concern, as mounting 
evidence demonstrates the existence of many biological functions of vitamin D, in 
addition to the classical functions of vitamin D related to regulation of calcium 
and phosphate homeostasis and bone metabolism.  
Additionally, vitamin D status has been implicated in the development of 
obesity-associated metabolic disorders (179). Human cross-sectional studies  
demonstrate that vitamin D deficiency is association with hyperglycemia (180, 
181), hyperinsulinemia (182), reduced pancreatic beta-cell function (183), and 
measures of insulin resistance (183). Further, early studies utilizing vitamin D-
deficient rats found that pancreatic insulin secretion was impaired compared to 
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that of vitamin D-replete rats (184, 185). The relationship between vitamin D 
supplementation and glycemic control remains controversial. In vitro studies 
demonstrate that 1,25(OH)2D enhances insulin sensitivity in skeletal muscle 
(186), a major contributor to global insulin sensitivity. However, recent meta-
analyses of randomized controlled trials designed to assess the impact of vitamin 
D supplementation on insulin sensitivity failed to show a positive effect of vitamin 
D supplementation on homeostatic model assessment of insulin resistance 
(HOMA-IR), or on 2-hour plasma glucose following an oral glucose tolerance test 
(OGTT) (187, 188). One meta-analysis did find small yet statistically significant 
reductions in fasting blood glucose and HbA1c levels in individuals with 
prediabetes who received vitamin D supplementation (187). The relationship 
between vitamin D and insulin sensitivity remains incompletely understood 
1.3 Vitamin D Plays a Role in Adipose Tissue Physiology 
1.3.1 Relationship between Vitamin D Status and Obesity 
The inverse relationship between vitamin D status and adiposity is well-
established: serum 25-hydrovyvitamin D [25(OH)D] levels are inversely 
correlated with measures of adiposity including fat mass, body mass index (BMI), 
and waist circumference (189-194). Several hypotheses have been studied 
regarding the nature of this relationship. One such hypothesis is that vitamin D 
deficiency plays a causative role in the development of obesity, which resulted in 
the execution of studies designed to determine the impact of vitamin D 
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supplementation on weight loss and obesity-associated comorbidities. The 
existing evidence however does not support this causal relationship (179).  
Analysis of intervention studies having a duration of 1 year and achieving serum 
25(OH)D of >85 nmol/L found no significant changes in BMI (195, 196). 
Consistent with these findings, participants given 2,000 IU/day vitamin D in a 
short randomized controlled trial experienced significant increases in serum 
25(OH)D and 1,25(OH)2D with no changes in energy expenditure or adipose 
tissue gene expression (197). Taken together, these studies indicate that vitamin 
D supplementation alone is not an effective means by which to induce weight 
loss. 
The inverse relationship between vitamin D deficiency and adiposity may 
be attributed to lifestyle factors that promote both of these conditions.  Examples 
would include a diet poor in vitamin D, and little outdoor exercise (and thus 
reduced solar ultraviolet radiation and endogenous production of vitamin D) (191, 
198). Alternatively, it has been postulated that obese individuals may have 
reduced circulating 25(OH)D due to sequestration of vitamin D and its 
metabolites in adipose tissue. The evidence is most compelling for the latter of 
these hypotheses.   
1.3.1.1 Sequestration of Vitamin D in Adipose Tissue 
It has been established that adipose tissue is a storage site of vitamin D 
(199-201). In rats, adipose tissue accounts or the majority of vitamin D storage, 
half stored as unmetabolized vitamin D and the other half stored as vitamin D 
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metabolites, esters, and other unidentified compounds (200). The inverse 
relationship between vitamin D status and adiposity may be explained by 
sequestration of the nutrient in adipose tissue. An investigation led by Wortsman 
et al. demonstrated that the increase in serum vitamin D3 following whole-body 
irradiation was 57% lower in obese than in age-matched lean controls (202). This 
occurred despite no significant difference in the cutaneous vitamin D precursor 7-
dehydrocholesterol between these two groups, and no difference in the 
conversion of 7-dehydrocholesterol to previtamin D3. Further, an inverse 
correlation was found between BMI and peak serum vitamin D2 concentrations 
following oral administration of 50,000 IU vitamin D2, suggesting that obesity-
associated vitamin D deficiency is likely due to its reduced bioavailability resulting 
from sequestration in adipose tissue depots (202). A study by Vimaleswaran et 
al. arrived at a similar conclusion upon employing a Mendelian randomization 
approach for determining directionality and causation of the association between 
vitamin D status and BMI (203). The results from this study reveal that a higher 
BMI was causally linked to reduced serum 25(OH)D levels, but the findings did 
not suggest that raising serum 25(OH)D levels will have a BMI lowering effect. 
While these studies clearly demonstrate that excessive adiposity underlies 
obesity-associated vitamin D deficiency, it is not yet known whether direct action 
of vitamin D on adipose tissue plays a role in this relationship. 
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1.3.1.2 Role of 1,25(OH)2D and the VDR in Adipogenesis 
Expansion of adipose tissue occurs as a result of the enlargement of 
adipocyte size (hypertrophy) and an increase in adipocyte number (hyperplasia). 
Both of these processes occur during adipocyte differentiation, in a process 
called adipogenesis. The vitamin D receptor, a nuclear receptor that 
heterodimerizes with RXR, is expressed in adipose tissue and is acutely 
upregulated during adipogenesis in vitro (204). Many in vitro studies using 
established cell lines have demonstrated 1,25(OH)2D regulation of preadipocyte 
differentiation.  
In mouse 3T3-L1 preadipocytes, differentiation is inhibited by 1,25(OH)2D 
via downregulation of C/EBPα and PPARγ expression and sequestration of RXR, 
resulting in downregulation of C/EBPβ (205-208). Further, upregulation of 
C/EBPβ corepressor eight twenty-one (ETO) by 1,25(OH)2D further reduces 
C/EBPβ activity and inhibits adipogenesis. More recently, Lee et al. demonstrate 
that in 3T3-L1 preadipocytes, 1,25(OH)2D promotes maintenance of WNT10B 
and nuclear β-catenin expression, suppressing PPARγ activity and preserving 
the preadipocyte phenotype (207). Additionally, it has been demonstrated that 
VDR knockdown inhibits adipogenesis in 3T3-L1 preadipocytes (206), and that 
VDR null mice exhibit an extremely lean phenotype with resistance to diet 
induced obesity (209-211).   
However, 1,25(OH)2D regulation of preadipocyte differentiation appears to 
be species-dependent. In porcine mesenchymal stem cells,1,25(OH)2D 
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stimulates differentiation towards an adipocyte phenotype by stimulating PPARγ, 
lipoprotein lipase (LPL), and aP2 expression (212). In human subcutaneous 
preadipocytes, differentiation is stimulated by 1,25(OH)2D, resulting in increased 
expression of FABP4 and LPL (213). Narvaez et al. conducted genomic profiling 
of primary cultures of human adipose-derived mesenchymal progenitor cells to 
define the role of 1,25(OH)2D and its VDR in adipogenesis, and found that 
1,25(OH)2D promoted lipid accumulation and enhanced expression of FABP4, 
FASN, and PPARγ (214).  The discrepancies observed between studies utilizing 
human versus mouse 3T3-L1 preadipocytes may be due to methodological 
differences, or due to differences in the roles of adipose tissue in energy balance 
between the two species. Regardless, 1,25(OH)2D appears to play a multifaceted 
role in the regulation of adipose tissue physiology. 
1.3.1.3 Regulation of Inflammation by 1,25(OH)2D 
During obesity, expansion of adipose tissue results in insufficient blood 
flow to the hypertrophic tissue, stimulating hypoxia, macrophage infiltration, and 
inflammation. In this state, secretion of adiponectin and other anti-inflammatory 
adipokines are reduced, while secretion of pro-inflammatory cytokines such as 
interleukin-6 (IL-6), TNFα, resistin, and MCP-1 are increased (215). While vitamin 
D regulation of adipose tissue inflammation remains incompletely defined, 
several in vitro studies have demonstrated that 1,25(OH)2D does act at several 
levels to modulate this system.  Studies by Zemel et al. utilizing 3T3-L1 and 
human adipocytes have found that 1,25(OH)2D exerts a pro-inflammatory effect, 
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inhibiting anti-inflammatory cytokine expression while stimulating expression of 
pro-inflammatory cytokines. In these studies, treatment of adipocytes with 
1,25(OH)2D increased expression of TNFα, IL-6, IL-8, macrophage colony-
stimulating factor (M-CSF), and macrophage inflammatory factor (MIF) (216-
218). Expression of M-CSF and MIF were ameliorated by calcium-channel 
antagonism with nifedipine, indicating that 1,25(OH)2D operates via a calcium-
dependent mechanism (218). 
However, not all studies have revealed consistent findings. In contrast to 
the pro-inflammatory properties identified by Zemel and colleagues, several 
recent investigations utilizing human preadipocytes and mature human 
adipocytes have identified an anti-inflammatory role of 1,25(OH)2D in adipocyte 
physiology. An investigation of the effects of high vitamin D and calcium intake in 
a Western diet on energy metabolism and inflammation revealed that mice on a 
Western diet, as expected, experienced reduced energy expenditure and excess 
fat accumulation compared to mice fed a control diet. Interestingly, mice fed a 
Western diet plus vitamin D and calcium experienced significantly higher fat 
deposition in AT and in the liver compared to mice fed a Western diet low in 
these nutrients. However, the Western diet-induced increase in circulating 
inflammatory markers IL-1β and  MCP-1 were ameliorated by high vitamin D and 
calcium (219). In vitro studies have yielded similar findings.  Investigations by 
Marcotorchino et al. found reductions in protein and mRNA expression of TNFα, 
IL-6, MCP-1, and IL-1β with 1,25(OH)2D treatment of human and 3T3-L1 
adipocytes (220). In human preadipocytes, 1,25(OH)2D reduced MCP-1, IL-6 and 
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IL-8 secretion under basal and proinflammatory conditions (221). These and 
additional studies provide evidence to support that the anti-inflammatory effects 
of 1,25(OH)2D on adipose tissue are via inhibition of the NFκB signaling pathway 
(220-223). 
Though many studies do demonstrate vitamin D regulation of adipose 
tissue inflammation in vitro and in vivo, this system does not appear to be as 
highly regulated by vitamin D in humans. Clinical intervention studies designed to 
examine the effect of vitamin D supplementation on markers of inflammation 
have failed to see improvements in systemic and AT inflammation. A double-
blind intervention study of 52 obese (BMI > 30 kg/m2), vitamin D-deficient 
(plasma 25(OH)D <50 nM) individuals failed to see an effect of 26 weeks of 
7,000 IU vitamin D3/day on any of the examined circulating inflammatory 
markers, including Hs-CRP, IL-6, MCP-1, adiponectin, leptin, MMP-9, and PAI-1, 
despite achieving plasma 25(OH)D concentrations of 110.2 ± 21.2 nM by the end 
of the intervention period (224). Further analysis by the same group also 
confirmed no change in AT markers of inflammation in these subjects following 
oral vitamin D supplementation (225). While 1,25(OH)2D appears to have largely 
anti-inflammatory effects in vitro and in vivo, more studies are needed in order to 
determine the physiological relevance of these findings in humans. 
1.3.1.4 Vitamin D Regulation of Energy Metabolism 
Vitamin D, or more specifically the vitamin D receptor, also appears to 
modulate energy metabolism. Recent investigations utilizing VDR knockout 
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(VDR-/-) mice have revealed that ablation of the VDR leads to reduced body 
weight, hyperphagia with resistance to diet-induced obesity, hypolipidemia, and 
hypoleptinemia (209-211). VDR null mice also exhibit increased UCP-1 
expression, energy expenditure, oxygen consumption and basal metabolism 
compared to wild-type (WT) mice (210). These findings of increased energy 
expenditure and resistance of VDR-null mice to diet-induced obesity has led to 
investigations of the role of the VDR in adipocyte energy and lipid metabolism 
(210, 226).   
An additional study by Wong et al. utilized the aP2 gene promoter to target 
the expression of human (h) VDR in adipocytes in mice (227).  In contrast to the 
VDR-null mice, aP2-hVDR Tg mice exhibited reduced locomotive activity and 
energy expenditure, and increased accumulation of fat mass compared to WT 
mice.  Adipose tissue of the transgenic mice exhibited reduced fatty acid β-
oxidation and expression of genes involved in the regulation of fatty acid 
transport, thermogenesis, and lipolysis. Collectively, these findings suggest a role 
for VDR regulation of energy metabolism in adipocytes, and it has been 
speculated that vitamin D storage within adipose tissue increases local vitamin D 
concentration and thus activation of the VDR, negatively affecting energy 
expenditure and exacerbating fat mass accumulation. However, the applicability 
of these findings in humans has yet to be determined. 
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1.3.1.5 1,25(OH)2D May Regulate Adipocyte Lipid Metabolism  
While limited data exist regarding direct effects of 1,25(OH)2D on 
adipocyte lipid metabolism, the hormone may modulate lipid metabolism 
indirectly via its relationship with calcium metabolism. It was previously noted that 
a high calcium diet suppressed renal 1,25(OH)2D production in aP2-agouti 
transgenic mice, leading to decreased intracellular Ca2+ ([Ca2+]i), stimulation of 
lipolysis, inhibition of lipogenesis, and reduced adiposity (228, 229). To 
determine whether this modulation of adipocyte lipid metabolism is a direct effect 
of inhibition of 1,25(OH)2D-induced [Ca2+]i, differentiated adipocytes from a 
human adipocyte cell line and primary-cultured human adipocytes were treated 
with 1,25(OH)2D for 48 hours, and intracellular [Ca2+]i, rate of lipolysis, and 
expression and activities of lipid metabolism enzymes examined.  Adipocytes 
exhibited a 1,25(OH)2D dose-responsive (1-50 nM) increase in [Ca2+]i (P<0.01), 
a 50-100% increase in FAS expression and activity (P<0.02), a 61% increase in 
GPDH activity (P<0.01), and 80% inhibition of isoproterenol-stimulated lipolysis 
(P<0.001) (230). Using an agonist (1α,25-dihydroxylumisterol3)  and antagonist 
(1β,25-(OH)2D3)  of the putative membrane vitamin D receptor (mVDR), the 
authors demonstrated that 1,25(OH)2D elicits a nongenomic response in 
adipocytes, resulting in stimulation of [Ca2+]i and corresponding modulation of 
lipid metabolism. Further study by the same group demonstrated that treatment 
of human adipocytes for 48 hrs with 1 nM 1,25(OH)2D simulated a 50% reduction 
in UCP2 mRNA and protein levels (P<0.002), and blocked isoproterenol- or fatty 
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acid-stimulated increases in UCP2 expression (231).  Collectively, the authors 
conclude that the anti-obesity effects of dietary calcium are, at least in part, via 
inhibition of 1,25(OH)2D production.   
Some investigations have been conducted to examine this relationship 
between calcium, vitamin D, and lipolysis in humans. Four studies have reported 
that obese individuals have high serum concentrations of 1,25(OH)2D compared 
to non-obese individuals (189, 190, 232, 233), and it has been suggested that 
1,25(OH)2D, via its ability to increase intracellular Ca2+ concentrations particularly 
in adipocytes, may exacerbate fat mass accumulation in those predisposed to 
obesity (228, 234).  However, these studies employed very small cohorts of 
obese subjects, all of whom appeared to have been Caucasian. To address this, 
a subsequent study was conducted by Parikh et al., in which the relationships 
between calciotropic hormones and body adiposity were examined in 154 healthy 
obese (BMI = 37.3 ± 5.8 kg/m2) and 148 healthy non-obese (BMI 25.6 ± 2.9 
kg/m2) individuals of Caucasian (62.9%), African-American (27.8%), and other 
(9.3%) race/ethnicities (235). In both Caucasian and African-American adults, it 
was found that serum 1,25(OH)2D was significantly lower in obese subjects 
relative to nonobese subjects (105.7 ± 41.1 vs. 124.8 ± 36.7pmol/liter; P < 
0.0001). Serum intact PTH was positively correlated with both BMI (r = 0.42; 
P<0.0001) and body fat mass (r = 0.37; P < 0.0001), while serum 25(OH)D and 
1,25(OH)2D were negatively correlated with BMI (25(OH)D: r = 0.4, P < 0.0001; 
1,25(OH)2D: r = 0.26; P < 0.0001) and body fat mass (25(OH)D: r  = 0.41; P < 
0.0001; 1,25(OH)2D: r = 0.25; P < 0.0001). These relationships existed 
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independent of age, sex, or race, and do not support the hypothesis that 
1,25(OH)2D exacerbates fat mass accumulation in the obese. 
While the effect of vitamin D on adipocyte differentiation, inflammation, 
and energy metabolism have been studied, the impact of vitamin D on lipid 
metabolism in adipocytes that have completed terminal differentiation is 





CHAPTER 2.  MATERIALS AND METHODS 
2.1 Chemicals and Reagents 
Dulbecco's Modification of Eagle's Medium (DMEM) was obtained from 
Corning (Manassas, VA).  Bovine calf serum was obtained from Thermo Fisher 
Scientific (Pittsburgh, PA). 1,25(OH)2D was obtained from Enzo Life Sciences 
(East Farmingdale, NY). Fetal bovine serum, trypsin, and penicillin/streptomycin 
were obtained from Life Technologies, Gibco-BRL (Rockville, MD). Protease 
inhibitors cocktail, essentially fatty acid-free bovine serum albumin (FA-Free 
BSA),trypan blue solution (0.4%), insulin (bovine), dexamethasone, 3-Isobutyl-1-
methylxanthine were obtained from Sigma-Aldrich (St. Louis, MO). Rosiglitazone 
was obtained from Cayman Chemical (Ann Arbor, MI). PKA inhibitor H-89 
dihydrochloride was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, 
CA). Antibodies for HSL, phospho-HSL (Ser565 and Ser660), perilipin, and 
GAPDH were purchased from Cell Signaling Technology, Inc. (Danvers, MA).  
2.2 Cell Culture 
3T3-L1 fibroblasts were obtained from American Type Culture Collection 
(ATCC CL-173; Manassas, VA), and cultured in DMEM containing 10% (vol:vol) 
FCS with 100 U/mL penicillin and 100 µg/mL streptomycin at 37⁰C and 5% CO2. 
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Adipocyte differentiation was initiated 2 days post-confluence (referred to as day 
0) using DMEMcontaining 10% (vol:vol) FBS, antibiotics, and a differentiation 
cocktail consisting of 1.0 µg/mL insulin, 0.5 mM isobutylmethylxanthine, 1.0 µM 
dexamethasone, and 2.0 µM rosiglitazone (236).  On day 2, this medium was 
replaced with DMEM containing 10% FBS, antibiotics, and 1.0 µg/mL insulin. 
Beginning on day 4, cells were maintained in DMEM containing 10% (vol:vol) 
FCS and antibiotics, and the medium was changed every 2 days.  Adipocytes 
were differentiated for 9 days, to allow for complete differentiation, and lipid 
accumulation (Figure 2.1). On day 9, 1,25(OH)2D (10 nM) was delivered to cells 
for the times indicated in 100% ethanol at a final ethanol concentration of <0.1%. 
For experiments lasting longer than 24 hours, cell medium containing 
1,25(OH)2D or vehicle was refreshed every 24 hours. Cell viability was assessed 
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 
trypan blue exclusion assays, according to manufacturer protocol. 
2.3 Triacylglycerol Quantification 
Following 1,25(OH)2D treatment, neutral lipids were extracted using a 3:1 
hexane:isopropanol solution, and dried under nitrogen gas. Neutral lipids were 
resuspended in chloroform containing 1% (vol:vol) triton X-100. Lipids were again 
dried under nitrogen gas, and resuspended in dH2O containing 2% (vol:vol) triton 
X-100. Triacylglycerol accumulation was assessed using a spectrophotometric 



















Figure 2.1. BODIPY staining of neutral lipids in differentiated 3T3-L1 adipocytes. 
Differentiated adipocytes were fixed with paraformaldehyde, and stained with 
BODIPY 493/503 (green) and DAPI (blue) to stain neutral lipids and nuclei, 




protocol.  Results are normalized against quantity of protein per well, which was 
quantified using the bicinchoninic acid assay (BCA assay: Pierce; Rockford, IL).  
2.4 Glycerol, Non-Esterified Fatty Acid, and Lactate Release  
Spent medium samples were collected after 24 hours of treatment and 
used for analysis of glycerol, NEFA, and lactate.  Glycerol and NEFA were 
quantified using spectrophotometric assay kits from Sigma-Aldrich (St. Louis, 
MO) and Wako Diagnostics (Richmond, VA), respectively. For PKA inhibition 
studies, following 48 hours of treatment with 1,25(OH)2D (10 nM) or vehicle, cells 
were pre-treated for two hours with PKA inhibitor H-89 (75 µM), with 1,25(OH)2D 
as indicated. Following pre-treatment, the medium was replaced with serum-free 
DMEM containing vehicle or 1,25(OH)2D and H-89 as indicated for an additional 
4 hours, after which the medium was collected for determination of glycerol 
release. Lactate secretion was determined using a spectrophotometric method 
based on the principle that in the presence of NAD+, lactate in spent media 
samples can be converted to pyruvate by lactate dehydrogenase. Hydrazine is 
added to destroy the pyruvate produced, allowing the reaction to run to the 
complete oxidation of all lactate molecules. The amount of NADH formed by the 
reaction is proportionate to the amount of lactate in the media, and is measured 
spectrophotometrically at 340 nm. All results are normalized against quantity of 
protein per well, which was quantified using the bicinchoninic acid assay (BCA 
assay: Pierce; Rockford, IL).  
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2.5 Intracellular Cyclic AMP Accumulation 
Cells were harvested into lysis buffer as described above. Intracellular 
cyclic AMP accumulation was determined using a commercially available kit from 
Enzo Life Sciences (East Farmingdale, NY), according to the manufacturer’s 
protocol. 
2.6 Fatty Acid Uptake 
Cells were washed with calcium/magnesium-free phosphate buffered saline 
(CMF-PBS, pH=7.4), incubated with 10 µM BODIPY® FL C16 (4,4-Difluoro-5,7-
Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3-Hexadecanoic Acid; Life 
Technologies, Carlsbad, CA) in 0.1% FA-Free BSA in Hanks’ balanced salt 
solution (HBSS; Gibco – Life Technologies, Carlsbad, CA) for 1 minute, and then 
washed twice with an ice-cold solution of 0.2% FA-Free BSA in HBSS. 
Fluorescence was measured using a Synergy H1 Multi-Mode Reader (BioTek 
Instruments, Inc.; Winooski, VT), and analyzed using Gen5™ Data Analysis 
Software (BioTek Instruments, Inc.).  The relative BODIPY FL C16 uptake is 
expressed as fluorescence intensity per well normalized to the total amount of 
protein per well. In separate experiments, cells were incubated in serum-free 
DMEM containing 1 mM palmitic acid (500,000 DPM/mL) in 3% BSA for 1 
minute, and then washed twice with an ice-cold solution of 0.2% FA-Free BSA in 
HBSS. Cells were lysed by incubating with lysis buffer (0.1 M NaOH, 0.2% (w:v) 
SDS) at 37°C for two hours. Cell lysates were transferred to a scintillation vial, 
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and assessed for radioactivity in a liquid scintillation counter (Tri-Carb 1600 TR 
Liquid Scintillation Analyzer, PerkinElmer, Waltham, MA). 
2.7 Fatty Acid Oxidation 
Fatty acid oxidation (FAO) was assessed by quantifying the production of 
14CO2 from [1-14C] palmitic acid as previously described (237). Cells were plated 
in 35 mm dishes, differentiated as described above, and incubated with 10 nM 
1,25(OH)2D for 4 days. To measure FAO, dishes were placed and sealed in 
wide-mouth jars with screw-top lids, and cells were incubated in serum-free 
DMEM containing 1 mM palmitic acid (500,000 DPM/mL) in 3% BSA for 3 hours 
at 37ᵒC and 5% CO2. After 3 hours, the reaction was terminated by injection of 5 
N perchloric acid to the cell culture dish. To trap 14CO2, 2-phenethylamine was 
injected into well inserts containing Whatman 1 filter papers located inside the 
jar. After 1 hour, filter papers were placed in vials with scintillation fluid and 
assessed for radioactivity in a liquid scintillation counter (Tri-Carb 1600 TR Liquid 
Scintillation Analyzer, PerkinElmer, Waltham, MA). Oxidation values were 
normalized to the protein content of treatment-matched control dishes. 
2.8 De Novo Lipogenesis:  
Cells were differentiated in 6-well tissue culture dishes as described 
above, and incubated with 10 nM 1,25(OH)2D for 4 days During the last 24 hours 
of treatment, 3T3-L1 adipocytes were incubated with 10 mM [13C2]acetate 
(Sigma-Aldrich, St. Louis, MO). Cells were harvested into 300 uL lysis buffer 
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containing 25 mM HEPES, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100. Lipid 
hydrolysis, extraction, derivatization and analysis by high pressure liquid 
chromatography/electrospray ionization-mass spectrometry (HPLC/ESI-MS/MS) 
were performed as previously described (238). Briefly, cell lysates were heated 
at 90ᵒC in a solution of acetonitrile:HCl (37%) (4:1, v/v) to hydrolyze fatty acids. 
After cooling to room temperature, fatty acids were extracted with hexane and 
dried under nitrogen gas. Fatty acids were resuspended in acetone, derivatized 
with 2-bromo-1-methylpyridinium iodide and 3-carbinol-1-methylpyridinium iodide 
to form 3-acyloxymethyl-1-methylpyridinium iodide (AMMP), and subjected to 
HPLC/ESI-MS/MS analysis. Substrate incorporation into 16:0, 16:1, 18:0, and 
18:1 fatty acids was assessed, and data are expressed percent of fatty acid with 
13C label, relative to vehicle. To determine the contribution of glucose as a 
substrate for de novo lipogenesis, in separate experiments, 3T3-L1 adipocytes 
were incubated in glucose-free DMEM containing a 1:1 mixture of D-[U-
13C]glucose (Sigma-Aldrich, St. Louis, MO) and non-labeled D-glucose, at a final 
glucose concentration of 4.5 g/L.  Incorporation of [U-13C]glucose into fatty acids 
during the last 24 hours of treatment was assessed as described above.  
2.9 Glucose Uptake and Consumption 
Basal and insulin-stimulated glucose uptake were assessed using the 2-
[1,2-3H(N)]-deoxy-D-glucose uptake assay. Cells were washed with 
calcium/magnesium free phosphate buffered saline (CMF-PBS, pH=7.4), and 
incubated with serum- and glucose-free DMEM for 2 hours at 37°C and 5% CO2. 
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Subsequently, cells were incubated in the presence or absence of insulin (100 
nM) for an additional 20 minutes at 37°C, before the 2-[1,2-3H(N)]-deoxy-D-
glucose uptake assay was initiated by the addition of serum- and glucose-free 
DMEM containing insulin (or vehicle), 2-deoxyglucose (100 µM, Sigma-Aldrich, 
St. Louis, MO) and 2-[1,2-3H(N)]-deoxy-D-glucose (1.0 µCi/mL, Perkin Elmer, 
Oak Brook, IL). Cells were incubated for a further 10 minutes, and the reaction 
was terminated by washing 3 times with ice-cold CMF-PBS containing phloretin 
(0.2 mM). Nonspecific uptake, determined in the presence of phloretin (0.2 mM, 
Sigma-Aldrich, St. Louis, MO), was subtracted from all values (239). Cells were 
lysed by incubating with lysis buffer (0.1 M NaOH, 0.2% (w:v) SDS) at 37°C for 
two hours. Cell lysates were transferred to a scintillation vial, and assessed for 
radioactivity in a liquid scintillation counter (Tri-Carb 1600 TR Liquid Scintillation 
Analyzer, PerkinElmer, Waltham, MA). Glucose uptake values were normalized 
to the protein content of treatment-matched control dishes. Glucose 
concentrations in spent media samples were measured using a commercially 
available kit (Cayman Chemicals, Ann Arbor, MI), utilizing the glucose oxidase-
peroxide reaction.  Glucose consumption was calculated using the difference 
between spent and fresh media samples, and data normalized to total protein. 
2.10 Western Blotting 
Cells were washed with calcium/magnesium free phosphate buffered 
saline (CMF-PBS, pH=7.4) and harvested on ice into lysis buffer containing 25 
mM HEPES, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, and 1% each of 
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protease and phosphatase inhibitor cocktails (Sigma-Aldrich, St. Louis, MO). 
Cells were briefly sonicated and cell debris was removed by centrifugation at 
12,000 RPM for 15 min at 4°C. Protein concentration was determined using the 
BCA assay. Proteins (20–30 μg) were resolved by SDS-PAGE on 7.5%, 10% or 
12% polyacrylamide gels (Bio-Rad Laboratories, Hercules, CA). Resolved 
proteins were transferred onto nitrocellulose membranes (Bio-Rad Laboratories, 
Inc.), and probed with specific antibodies against proteins as indicated. Antigen-
antibody complexes were detected using the Lumiglo Reagent (Cell Signaling 
Technology, Inc.). Densities of immunoreactive bands were assessed using UN-
SCAN-IT gel analysis software (Silk Scientific, Orem, UT). Densities of the bands 
were in the linear range of detectability. Results are expressed as fold change of 
respective protein/GAPDH, or phosphorylated protein over total. 
2.11 RNA Isolation and Analysis 
 RNA was isolated using TriReagent (Molecular Research Center, 
Cincinnati, OH) according to the manufacturer’s protocol. Reverse transcription 
of total RNA was performed using MMLV reverse transcriptase (Promega, 
Madison, WI). Real-time quantitative PCR was performed using the Ultra-Fast 
SYBR® Green QPCR Master Mix (Agilent Technologies, Santa Clara, CA). The 
mRNA abundance of target genes were determined using the threshold cycle 
(Ct) value. Data are normalized to 18S expression, and expressed as fold 
change relative to vehicle. Primers used are shown in Table 4. 
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2.12 Transfection of 3T3-L1 Adipocytes 
 The pyruvate carboxylase (PC) plasmid was synthesized and obtained 
through OriGene Technologies (Rockville, MD). The PC transcript variant 1 clone 
was synthesized, and inserted into the pCMV6-Neo vector downstream of the 
cytomegalovirus (CMV) immediate-early promoter. The plasmid was transiently 
transfected into differentiated 3T3-L1 adipocytes using Lipofectamine 3000 
(Invitrogen, Carlsbad, CA), according to manufacturer protocol.   
2.13 Statistical Analysis 
Values are presented as mean ± SEM. Results are expressed compared 
to vehicle by the Student’s t-test (LSD) or by analysis of variance (ANOVA), with 
P<0.05 considered statistically significant. All experiments were performed at 




























Gene Primer information 
ACC1 Forward: 5'- GCGTCGGGTAGATCCAGTT-3' 
 Reverse: 5'- CTCAGTGGGGCTTAGCTCTG-3' 
ACC2 Forward: 5'- ACTGTCCTGAGATCCCCCTC-3' 
  Reverse: 5'- GGACCCAGTCCTTCAGCTTC-3' 
AQP7 Forward: 5'- TGTCGCTAGGCATGAACTCC-3' 
 Reverse: 5'- CAGGAGATCCCAAGGAGTGG-3' 
CPT-1α Forward: 5'- CTGCAGACTCGGTCACCACT-3' 
  Reverse: 5'- ACACCCACCACCACGATAAG-3' 
FAS Forward: 5'- ACCACTGCATTGACGGCCGG-3' 
 Reverse: 5'- GGGTCAGGCGGGAGACCGAT-3' 
GLUT1 Forward: 5'- GTGACGATCTGAGCTACGGG-3' 
  Reverse: 5'- GAGAGACCAAAGCGTGGTGA-3' 
GLUT4 Forward: 5'- GTGACTGGAACACTGGTCCTA-3' 
 Reverse: 5'- CCAGCCACGTTGCATTGTAG-3' 
hPC Forward: 5'- ATGTTGCCCACAACTTCAGCAAGC-3' 
  Reverse: 5'- AGTTGAGGGAGTCAAACACACGGA-3' 
PC Forward: 5'- TCCTCTATCACGTCCTCTGTGT-3' 
 Reverse: 5'- ACATTTGGGGAGGCAACAGG-3' 
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CHAPTER 3. 1,25-DIHYDROXYVITAMIN D REGULATES TRIACYLGLYCEROL 
ACCUMULATION IN 3T3-L1 ADIPOCYTES 
3.1 1,25(OH)2D Regulates Lipid Metabolism in 3T3-L1 Adipocytes 
3.1.1 1,25(OH)2D Reduces Triacylglycerol Accumulation in 3T3-L1 Adipocytes 
Previous studies have demonstrated the ability of 1,25(OH)2D to inhibit the 
onset of adipogenic gene expression, and consequent lipid accumulation, during 
3T3-L1 preadipocyte differentiation (206, 208, 240). However, whether 
1,25(OH)2D impacts lipid metabolism in adipocytes that have completed terminal 
differentiation is not known. To determine the impact of 1,25(OH)2D on lipid 
metabolism in mature adipocytes that have completed terminal differentiation, 
3T3-L1 preadipocytes were first differentiated for 9 days. By Day 9, cells had 
achieved complete differentiation, and cells contained large lipid droplets.  To 
determine whether 1,25(OH)2D modulates triacylglycerol (TAG) accumulation in 
mature adipocytes, differentiated cells were stimulated with 1,25(OH)2D (10 nM) 
for 4 or 7 days, and total triacylglycerol levels assessed. Following 4 days of 
treatment, triacylglycerol accumulation was 21% lower in 1,25(OH)2D-treated 
cells compared to vehicle (p=0.01) when normalized to protein content (Figure 
3.1).  The TAG-lowering effect of 1,25(OH)2D persisted following 7 days of 
treatment, demonstrating achievement of a stable state of reduced lipid storage 
61 
 
(Figure 3.1). Cell viability, assessed using the MTT (Figure 3.2A) and trypan blue 
exclusion assays (Figure 3.2B), was not affected following 4 days of 1,25(OH)2D 
treatment. These data indicate that 1,25(OH)2D acts on mature adipocytes to 
stimulate a reduction in lipid storage in the absence of cytotoxicity. 
3.1.2 1,25(OH)2D Stimulates Glycerol Release in 3T3-L1 Adipocytes 
Triacylglycerol accumulation in adipocyte lipid droplets is a balance 
between storage of fatty acids that are taken up by the cell or synthesized de 
novo, and release of fatty acids that are hydrolyzed from TAG by lipolysis. 
Hydrolysis of stored TAG in adipocytes by lipolysis allows for the release of fatty 
acids from the cell, so that they may be used as an energy source for other 
tissues such cardiac and skeletal muscle. Lipolysis is a highly regulated process, 
and disturbances in the regulation of this process underlie several metabolic 
disorders, including dyslipidemia and insulin resistance (74). To determine 
whether 1,25(OH)2D enhances rates of basal lipolysis, glycerol and non-
esterified fatty acid (NEFA) release in response to 1,25(OH)2D were assessed. 
When triacylglycerol stores are completely hydrolyzed to provide energy 
substrates for use by other tissues, glycerol and non-esterified fatty acid moieties 
are released from the lipid droplet at a 3:1 molar ratio. While fatty acids may be 
re-esterified, oxidized, or released from the cell upon hydrolysis from the lipid 
droplet, glycerol kinase activity is negligible in white adipose tissue, meaning that 
glycerol released during lipolysis cannot be phosphorylated and used for TAG 
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synthesis (76).  Therefore, release of glycerol from the cell is frequently used as 
an indicator of lipolysis.  
Glycerol release was stimulated by 1,25(OH)2D following 1-4 days of 
treatment, with a maximal increase of 66% occurring after 2 days (p<0.001) 
(Figure 3.3). No change in glycerol release was observed within 1-8 hours of 
treatment (data not shown), suggesting genomic or indirect action of 1,25(OH)2D 
rather than activation of a rapid signaling pathway. Consistent with an increase in 
glycerol release, mRNA expression of the glycerol transporter aquaporin 7 
(AQP7) was increased by 27% by 1,25(OH)2D after 2 days (P<0.05) (Figure 3.4).  
However, despite a 66% increase in glycerol release with 1,25(OH)2D 
treatment, NEFA accumulation in the cell medium was below the limit of 
detection in both vehicle- and 1,25(OH)2D-treated cells, and did not change 
dramatically with 1,25(OH)2D (data not shown). High rates of fatty acid re-
esterification occur during lipolysis in WAT; 30-100% of fatty acids in the basal 
state, and 10-20% of those freed in response to lipolytic stimuli may be re-
esterified to TAG in a process termed futile TAG/FA cycling (73, 90-92). These 
data suggest that under basal and 1,25(OH)2D-stimulated conditions, either the 
majority of fatty acids that are released are either being re-esterified as TAG or 
the glycerol that is being released in response to 1,25(OH)2D is not of lipolytic 
origin.  
To explore the potential impact of 1,25(OH)2D on TAG hydrolysis, 
regulators of lipolytic action were investigated.  Chemical inhibition of protein 
kinase A (PKA) with H-89 dihydrochloride completely prevented 1,25(OH)2D 
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stimulation of glycerol release (Figure 3.5A), demonstrating that PKA activity is 
necessary for 1,25(OH)2D-stimulated lipolysis or release of glycerol. Additionally, 
phosphorylation of hormone sensitive lipase (HSL) at PKA phosphorylation site 
Ser660 was significantly increased with 1,25(OH)2D treatment (Figure 3.5B), 
while no change in phosphorylation level was observed at the AMPK 
phosphorylation site Ser565 (data not shown). Further, despite a reduction in 
ATGL protein expression, the protein expression of ATGL cofactor CGI-58 is 
significantly increased in response to 1,25(OH)2D treatment (Figure 3.5C).  
Given these 1,25(OH)2D-induced changes in the lipolysis signaling 
pathway, that the glycerol released in response to 1,25(OH)2D is due to 
hydrolysis of TAG remains a possibility.  However, not all data are consistent with 
1,25(OH)2D stimulation of TAG hydrolysis. First, the reduction in TAG 
accumulation after 4 days in response to 1,25(OH)2D cannot quantitatively 
sustain the increase in glycerol release that is stimulated by 1,25(OH)2D. As 
described above, no increase in NEFA release was observed with 1,25(OH)2D 
stimulation. Further, after two days of treatment, during maximal 1,25(OH)2D-
stimulated glycerol release, intracellular accumulation of cAMP was not altered 
by 1,25(OH)2D (Figure 3.6). PKA activation, which occurs during TAG hydrolysis, 
is stimulated by intracellular accumulation of cyclic AMP (cAMP) (241). Lack of 
intracellular cAMP accumulation and NEFA release are not consistent with PKA-
mediated TAG hydrolysis, and collectively, these data suggest that the glycerol 
released in response to 1,25(OH)2D is not primarily due to hydrolysis of TAG.  
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There are two alternate potential sources of glycerol that could be 
contributing to the pool of free glycerol released from the adipocytes. First, 
glycerol may be synthesized from glucose during glycolysis. Second, glycerol 
may be synthesized from glucose-derived pyruvate or lactate, by a process 
called glyceroneogenesis (76). In response to 1,25(OH)2D, whether the released 
glycerol is of lipolytic or of glycolytic/glyceroneogenic origin is not yet clear. The 
possibility of 1,25(OH)2D stimulation of glycerol release that is of 
glycolytic/glyceroneogenic origin is explored further in Chapter 3.2. 
3.1.3 1,25(OH)2D Stimulates Fatty Acid Uptake and Oxidation in 3T3-L1 
Adipocytes 
Another mechanism that can influence TAG accumulation is uptake of 
fatty acids.  To determine whether 1,25(OH)2D impacts the cells’ ability to take up 
exogenous fatty acids, uptake of BODIPY FL C16, a fluorescent C16:0 fatty acid, 
was assessed following 1, 2, 3, and 4 days of 1,25(OH)2D stimulation. 
Interestingly, despite a net reduction in TAG storage achieved following 4 days of 
1,25(OH)2D stimulation, BODIPY fatty acid uptake was significantly increased in 
response to 1,25(OH)2D at 24 hours (P<0.05), and remained elevated throughout 
the 4 days of treatment (Figure 3.7). These data indicate that 1,25(OH)2D does 
not impair the cells’ ability to take up exogenous fatty acids. 
In addition, fatty acid balance and changes in TAG accumulation are 
influenced by fatty acid oxidation.  To determine whether 1,25(OH)2D alters fatty 
acid oxidation in 3T3-L1 adipocytes, rates of β-oxidation were measured in 
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vehicle- and 1,25(OH)2D-treated cells. To quantify complete oxidation of fatty 
acids, 14CO2 production was assessed in response to stimulation by 1 mM 
palmitic acid, as described in Materials and Methods. Compared to vehicle-
treated cells, which exhibited a 14CO2 production rate of 0.624 nmol·hr-1·mg 
protein-1, those stimulated with 1,25(OH)2D for four days exhibited a 14CO2 
production rate of 1.55 nmol·hr-1·mg protein-1, an increase of 148% (p=0.002) 
(Figure 3.8A). This 2.5-fold increase in FAO is interesting, as 1,25(OH)2D 
reduces the mRNA expression of the FAO rate-limiting enzyme carnitine 
palmitoyltransferase I (CPT-1) by 56% after 4 days (p<0.01), while increasing the 
mRNA expression of acetyl-CoA carboxylase 2 (ACC2) by 48% (p=0.02) (Figure 
3.8B). When glucose is available, this isoform of ACC is responsible for the 
production of malonyl-CoA from glucose-derived acetyl-CoA. Production of 
malonyl-CoA inhibits CPT-1, and consequently, oxidation of fatty acids.  
Expression of FAO-related genes in response to 1,25(OH)2D are therefore not 
indicative of FAO activity in 3T3-L1 adipocytes. 
After 4 days of treatment, BODIPY FL C16 uptake was increased by 
approximately 1.8-fold in 1,25(OH)2D- vs vehicle-treated cells. At this same time 
point, oxidation of exogenously supplied palmitic acid was increased 
approximately 2.5-fold by 1,25(OH)2D. To determine if the increase in FAO is a 
consequence of increased ability to take up fatty acids, measurement of fatty 
acid uptake under the same conditions as those used for FAO experiments was 
assessed. In response to 1 mM palmitic acid, [1-14C] palmitic acid uptake was not 
significantly different in 1,25(OH)2D- compared to vehicle-treated cells (Figure 
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3.8C). A possible explanation for the discrepancy between the impact of 
1,25(OH)2D on the uptake of palmitic acid vs. that of BODIPY FL C16 is that 
1,25(OH)2D may alter the Km of fatty acid transporters, allowing regulation of 
fatty acid uptake to be observed under conditions where fatty acid uptake in 
response to increasing extracellular fatty acids is linear. If this is the case, such 
regulation may not be observed in response to relatively high fatty acid 
concentrations such has the 1 mm palmitic acid used to measure fatty acid 
oxidation. Regardless, these data demonstrated that 1,25(OH)2D stimulates fatty 
acid oxidation in 3T3-L1 adipocytes, independently of its effect on fatty acid 
uptake. This increase in fatty acid oxidation may contribute to the reduction in 










Figure 3.1. 1,25(OH)2D reduces triacylglycerol accumulation in 3T3-L1 
adipocytes.  Differentiated 3T3-L1 adipocytes were treated with vehicle or 
1,25(OH)2D (10 nM) for 4 or 7 days before analysis as indicated. Triacylglycerol 
accumulation in adipocytes was assessed using a commercially available kit. 





Figure 3.2. 1,25(OH)2D does not affect cell viability.  3T3-L1 adipocytes were 
treated with 1,25(OH)2D (10 nM) for 4 days, and cell viability was assessed using 
the MTT (A) and Trypan Blue Exclusion (B) assays (n=6-8/group). No significant 












Figure 3.3. 1,25(OH)2D stimulates glycerol release in 3T3-L1 adipocytes. 
Differentiated 3T3-L1 adipocytes were treated with vehicle or 1,25(OH)2D (10 
nM) for 1-4 days as indicated.  Glycerol release was assessed in spent media 
samples by quantitative enzymatic determination of free glycerol using a 













Figure 3.4. Aquaglyceroporin mRNA expression is upregulated by 1,25(OH)2D . 
Differentiated 3T3-L1 adipocytes were treated with vehicle or 1,25(OH)2D (10 
nM) for 2 days.  The mRNA expression of glycerol transporter AQP7 is 
















Figure 3.5. 1,25(OH)2D-induced glycerol release is PKA-dependent. 
Differentiated adipocytes were treated with 1,25(OH)2D (10 nM) or vehicle for 2 
days, and then harvested in lysis buffer. A) Inhibition of PKA prevents 
1,25(OH)2D-induced glycerol release (n=3/group). B) 1,25(OH)2D stimulates 
phosphorylation of HSL at PKA phosphorylation site Serine 660. Phosphorylation 
of HSL at the residues indicated was determined by Western blot as described in 
Materials and Methods. Data are expressed relative to total HSL protein 
expression (n=3/group). C) 1,25(OH)2D regulates CGI-58 and ATGL protein 
expression. Data are normalized to expression of actin (n=3/group). *P<0.05 









Figure 3.6. 1,25(OH)2D does not stimulate intracellular cAMP accumulation.  
Differentiated 3T3-L1 adipocytes were treated with 1,25(OH)2D (10 nM) or 
vehicle for 48 hours. As a positive control, some cells were stimulated with 
isoproterenol (10 µM) for two hours prior to harvest. Intracellular cAMP 
accumulation was determined as described in Materials and Methods. Data are 









Figure 3.7. 1,25(OH)2D stimulates fatty acid uptake in 3T3-L1 adipocytes. 
Differentiated 3T3-L1 adipocytes were treated with 1,25(OH)2D (10 nM) or 
vehicle for 1-4 days as indicated. Fatty acid uptake was determined following a 1-
minute incubation with BODIPY FL C16 (10 µM) as described in Materials and 
Methods. The relative BODIPY FL C16 uptake is expressed as fluorescence 
intensity per well, normalized to the total amount of protein. *P<0.05 compared to 








Figure 3.8. 1,25(OH)2D stimulates fatty acid oxidation in 3T3-L1 adipocytes. 
 Differentiated 3T3-L1 adipocytes were stimulated with 1,25(OH)2D (10 nM) or 
vehicle for 4 days. A) Complete oxidation of [1-14C] palmitic acid. Fatty acid 
oxidation was assessed as described in Materials and Methods (n=4/group). B) 
1,25(OH)2D regulates carnitine palmitoyltransferase I (CPT-1) and acetyl-CoA 
carboxylase 2 (ACC2) mRNA expression (n=3/group).  C) Uptake of [1-14C] 




3.2 1,25(OH)2D Regulates Glucose Metabolism and Utilization in 3T3-L1 
Adipocytes 
3.2.1 1,25(OH)2D Reduces Glucose and Acetate Incorporation into Fatty Acids 
in 3T3-L1 Adipocytes: 
The previously described studies demonstrate that 1,25(OH)2D stimulates 
PKA-dependent glycerol release and oxidation of fatty acids. While it remains 
unclear whether the observed glycerol release is of TAG or glyceroneogenic 
origin, it is likely that these alterations in lipid metabolism, particularly the 
elevated fatty acid oxidation, increase cellular energy expenditure and contribute 
to the reduction in TAG accumulation that is stimulated by 1,25(OH)2D. The 
studies described within examine the impact of 1,25(OH)2D on glucose 
metabolism and utilization in 3T3-L1 adipocytes.   
Glucose uptake by adipocytes plays a critical role in the maintenance of 
glucose homeostasis (74). In addition to glucose being a source of ATP for the 
adipocyte, it is estimated that 20-25% of the glucose consumed by adipocytes is 
used for the synthesis of fatty acids (77). To determine whether 1,25(OH)2D 
reduces glucose utilization for the synthesis of fatty acids, differentiated 3T3-L1 
adipocytes were stimulated with 1,25(OH)2D or vehicle for four days. During the 
final 24 hours of 1,25(OH)2D treatment, cell medium was replaced with 
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glucose-free DMEM, with D-glucose and D-[U-13C]glucose added at a 1:1 ratio to 
a final glucose concentration of 4.5 g/L. Lipid extraction and hydrolysis of fatty 
acids were performed as described in Materials andMethods, and incorporation 
of the 13C isotope into palmitic, palmitoleic, stearic, and oleic acids was assessed 
using HPLC/ESI-MS/MS. These four fatty acids comprise approximately 80% of 
the cellular fatty acid pool (242). Compared to vehicle-treated cells, 1,25(OH)2D 
stimulated a 28% reduction in 13C incorporation into these fatty acids (p<0.001) 
(Figure 3.9), demonstrating a reduced contribution of glucose as a substrate for 
de novo lipogenesis. This shift away from glucose utilization for de novo 
lipogenesis may contribute to the reduction in TAG that is stimulated by 
1,25(OH)2D. 
To determine whether 1,25(OH)2D reduces glucose incorporation into fatty 
acids by decreasing the rate of fatty acid synthesis in adipocytes, differentiated 
3T3-L1 adipocytes were treated as described above, and during the last 24 hours 
of treatment cells were incubated with 10 mM [13C2]acetate was added to the cell 
culture medium.  Cytosolic acetate serves as a substrate for fatty acid synthesis, 
and its incorporation into fatty acids serves as an indicator of lipogenesis. Lipid 
extraction and hydrolysis of fatty acids were performed as described above, and 
[13C2]acetate incorporation into palmitic, palmitoleic, stearic, and oleic acids was 
assessed using HPLC/ESI-MS/MS. Compared to vehicle-treated cells, those 
stimulated with 1,25(OH)2D exhibited a 9% reduction in acetate incorporation into 
fatty acids (p=0.026) (Figure 3.10). This reduction in acetate incorporation into 
fatty acids suggests that the enzymatic activity of acetyl CoA carboxylase 1 
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(ACC1), the rate-limiting step of lipogenesis, or of fatty acid synthase (FAS), is 
inhibited by 1,25(OH)2D. While the mRNA expression of acetyl-CoA carboxylase 
1 (ACC1), the ACC isoform responsible for supplying the malonyl-CoA pool for 
the synthesis of fatty acids, is not significantly different in vehicle- compared to 
1,25(OH)2D-treated adipocytes (Figure 3.11). However, fatty acid synthase (FAS) 
mRNA expression is significantly reduced by 1,25(OH)2D (Figure 3.11). 
Regardless, the relatively small magnitude of change in acetate compared to 
glucose incorporation into fatty acids suggests additional regulation of processes 
upstream of fatty acid synthesis by 1,25(OH)2D, at the level of glucose uptake or 
oxidation.  
3.2.2 1,25(OH)2D Impacts Basal and Insulin-Stimulated 2-deoxglucose Uptake 
in 3T3-L1 Adipocytes: 
 To determine whether 1,25(OH)2D reduces glucose incorporation into fatty 
acids by altering glucose uptake in 3T3-L1 adipocytes, glucose uptake was 
assessed after 4 days of 1,25(OH)2D treatment using the 2-deoxyglucose uptake 
assay as described in Chapter 2 (Materials and Methods). Compared to vehicle-
treated cells, those stimulated with 1,25(OH)2D exhibited a 62% increase in basal 
2-deoxyglucose uptake (p<0.01) (Figure 3.12A). Basal glucose uptake is under 
the control of the facilitated diffusion glucose transporter 1 (GLUT1), which is 
encoded by the SLC2A1 gene. While the highest levels of GLUT1 expression are 
observed in the brain, blood-brain barrier, erythrocytes, and fetal tissues, it is 
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expressed ubiquitously in tissues and cell cultures (102, 243). The mRNA 
expression of GLUT1 was not changed with 1,25(OH)2D treatment (Figure 3.13).  
While basal glucose uptake was significantly higher in 1,25(OH)2D- 
compared to vehicle-treated cells, insulin-stimulated 2-deoxyglucose uptake was 
not changed with 1,25(OH)2D treatment (Figure 3.12A). Thus, the fold increase in 
2-deoxyglucose uptake with acute insulin stimulation, a measure of insulin 
sensitivity, was significantly reduced by 28% in response to 1,25(OH)2D (p=0.04) 
(Figure 3.12B). Insulin-stimulated glucose uptake in skeletal muscle and adipose 
tissue is under the control of the GLUT4 glucose transporter, encoded by the 
SLC2A4 gene (102, 243). Consistent with a reduction in insulin sensitivity, mRNA 
expression of the insulin-responsive GLUT4 glucose transporter was reduced by 
36% in response to 1,25(OH)2D (p=0.01) (Figure 3.13). 
 In addition to acute basal and insulin-stimulated 2-deoxyglucose uptake, 
consumption of glucose and lactate secretion over a 24-hour period were also 
assessed. Though rates of basal 2-deoxyglucose uptake were elevated in 
response to 1,25(OH)2D, glucose consumption (Figure 3.14A) and lactate 
secretion (Figure 3.14B) over 24 hours was not affected. The discrepancy 
between the acute 2-deoxyglucose uptake and 24-hour glucose consumption 
data may be explained by the substrate concentrations used in each of these two 
studies. Under experimental conditions where substrate availability is less than 
the saturation concentration for a transporter, such as the 100 µM 2-
deoxyglucose used for glucose uptake experiments, alterations in the transporter 
Km (half-saturation concentration) may be observed. However, under 
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experimental conditions where substrate availability exceeds the saturation 
concentration for a transporter, such as the 25 mM D-glucose used in glucose 
consumption studies, facilitated diffusion of glucose across the membrane is at 
maximal capacity under basal conditions. In this case, alterations in GLUT1 Km, 
if applicable, would not be detected.  
3.2.3 1,25(OH)2D Reduces Pyruvate Carboxylase mRNA Expression  
Our data indicate that 1,25(OH)2D reduces the utilization of glucose as a 
substrate for de novo lipogenesis, without altering 24-hour glucose consumption. 
Previous studies from our laboratory demonstrate that 1,25(OH)2D reduces 
glycolysis and glucose flux into the TCA cycle in Harvey-ras oncogene 
transfected MCF10A cells, a model of early breast cancer progression, via 
negative regulation of the pyruvate carboxylase (PC) gene (unpublished data).  
In these transformed breast epithelial cells, the mRNA expression of PC was 
reduced by 24% as early as 24 hours, and protein expression was reduced by 
25% following 48 hours of 1,25(OH)2D stimulation.  Mutation analysis of the PC 
promoter suggested the presence and functionality of a negative VDRE, 
suggesting that 1,25(OH)2D regulates glucose metabolism via regulation of the 
PC gene. These data, along with the those obtained from our current studies, 
raised the question of whether 1,25(OH)2D regulates pyruvate carboxylase 
metabolism, and thus lipid accumulation, in 3T3-L1 adipocytes. 
It has previously been demonstrated that perturbed pyruvate metabolism 
impacts triacylglycerol accumulation in 3T3-L1 adipocytes (244). In these studies, 
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chemical inhibition of pyruvate carboxylase by 5 and 10 mM phenylacetate 
reduced TAG accumulation by 21 and 34%, respectively, after 8 days. Consistent 
with inhibition of glycolysis, release of glycerol and lactate were significantly 
increased by PC inhibition. Flux estimates indicated that reduced de novo fatty 
acid synthesis contributed to the reduction in TAG accumulation. Cytosolic 
acetyl-CoA, derived from cleavage of citrate that is exported from the 
mitochondria, is required for the synthesis of fatty acids. When de novo fatty acid 
synthesis is occurring, the mitochondrial citrate pool becomes drained. The 
anaplerotic function of PC is to supply oxaloacetate to the mitochondria TCA 
cycle intermediate pool. Therefore, inhibition of PC reduces the amount of 
substrate availability for the synthesis of fatty acids. These studies support the 
critical role of PC in regulating TAG accumulation. 
In our studies, 1,25(OH)2D reduces glucose utilization as a substrate for 
fatty acid synthesis. Additionally, 1,25(OH)2D stimulates a 41% reduction in 
pyruvate carboxylase mRNA expression in 3T3-L1 adipocytes after 2 days 
(p<0.01) (Figure 3.15). It has been demonstrated that PC enzymatic activity 
directly correlates with mRNA expression (245). We therefore hypothesized that 
1,25(OH)2D reduces glucose incorporation into fatty acids by reducing flux into 
the TCA cycle via inhibition of PC enzymatic activity. 
To test this hypothesis, the human PC gene was overexpressed in 
differentiated 3T3-L1 adipocytes, and glucose incorporation into fatty acids was 
assessed. A 6.6-fold increase in PC mRNA abundance was achieved with 
transfection of the PC plasmid (Figure 3.16). As expected, overexpression of PC 
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significantly increased glucose incorporation into the cellular pool of palmitic, 
palmitoleic, stearic, and oleic acids (Figure 3.17), while reducing secretion of 
glycerol (Figure 3.18A) and lactate (Figure 3.18B). If 1,25(OH)2D reduces 
glucose incorporation into fatty acids by reducing PC enzymatic activity, there 
would be no effect of 1,25(OH)2D in PC-overexpressing cells. However, in cells 
overexpressing PC, 1,25(OH)2D significantly reduced glucose incorporation into 
fatty acids, to levels similar to those in control 1,25(OH)2D-treated cells (Figure 
3.17). Moreover, in PC-overexpressing cells, 1,25(OH)2D significantly increased 
glycerol (Figure 3.18A) and  lactate (Figure 3.18B) secretion, to levels similar of 
those observed in control cells. Collectively, these data suggest that 1,25(OH)2D 
does not regulate glucose metabolism and subsequent triacylglycerol 
accumulation by altering PC enzymatic activity. 
3.2.4 Inhibition of Glycolysis Blunts 1,25(OH)2D-Stimulation of Glycerol Release 
Previous studies have demonstrated that in the presence of high glucose 
concentrations, adipocytes dispose of glucose as lactate and glycerol, potentially 
as a defense mechanism against excess energy substrate availability (95, 96). 
To determine whether 1,25(OH)2D induces glycerol release by stimulating 
hydrolysis of TAG or by stimulating synthesis of glycerol through 
glycolysis/glyceroneogenesis, 3T3-L1 adipocytes were stimulated with 
1,25(OH)2D in the presence or absence of 2-deoxyglucose (2-DG, 20 mM), an 
inhibitor of glycolysis (246, 247). By inhibiting glycolysis, the substrate availability 
for synthesis of glycerol via glycolysis and glyceroneogenesis becomes limited.  
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Observation of the impact of 1,25(OH)2D under these conditions will help 
elucidate whether 1,25(OH)2D stimulates hydrolysis of TAG, or synthesis of 
glycerol via glycolysis/glyceroneogenesis. 
In vehicle-treated cells, 2-DG stimulated a 3.4-fold increase in glycerol 
release within 24 hours (p<0.01) (Figure 3.19). This glycerol is likely derived from 
TAG hydrolysis in response to limited ATP availability from glucose. If 
1,25(OH)2D stimulates glycerol release by stimulating hydrolysis of TAG, an 
additive effect of 1,25(OH)2D on glycerol release would be observed. However, 
1,25(OH)2D has no further effect on 2-DG-stimulatd glycerol release after 24 
hours, and similar patterns of glycerol release were observed following 2-4 days 
of 2-DG and 1,25(OH)2D treatment (Figure 3.19). Collectively, these data are 
consistent with 1,25(OH)2D stimulation of glycerol synthesis via glycolysis and/or 










Figure 3.9. 1,25(OH)2D reduces glucose incorporation into fatty acids.  
Differentiated 3T3-L1 adipocytes were stimulated with 1,25(OH)2D (10 nM) or 
vehicle for 4 days. Cells were incubated with D-[U-13C]glucose during the last 24 
hours of treatment as described in Materials and Methods, and substrate 
incorporation into the cellular pool of palmitic, palmitoleic, stearic, and oleic acids 
was assessed using HPLC/ESI-MS/MS. Data are as the percent of labeled fatty 











Figure 3.10. 1,25(OH)2D reduces acetate incorporation into fatty acids. 
Differentiated 3T3-L1 adipocytes were stimulated with 1,25(OH)2D (10 nM) or 
vehicle for 4 days. Cells were incubated with [13C2]acetate during the last 24 
hours of treatment as described in Materials and Methods, and substrate 
incorporation into the cellular pool of palmitic, palmitoleic, stearic, and oleic acids 
was assessed using HPLC/ESI-MS/MS. Data are as the percent of labeled fatty 













Figure 3.11. Effect of 1,25(OH)2D on lipogenic gene expression.  Differentiated 
3T3-L1 adipocytes were treated with vehicle or 1,25(OH)2D (10 nM) for 4 days. 
A) The mRNA expression of acetyl CoA carboxylase 1 (ACC1) is not significantly 
changed by 1,25(OH)2D. B) 1,25(OH)2D significantly reduces fatty acid synthase 








































Figure 3.12. 1,25(OH)2D stimulates 2-deoxyglucose uptake in 3T3-L1 
adipocytes.  Differentiated 3T3-L1 adipocytes were treated with 1,25(OH)2D (10 
nM) or vehicle for 4 days. A) 2-deoxyglucose uptake was determined following a 
20-minute incubation with 2-[1,2-3H(N)]-deoxy-D-glucose (100 µM) as described 
in Materials and Methods. 2-deoxyglucose uptake is expressed as nmol•min-1•mg 
protein-1, and is normalized to total protein (n=4/group). B) 1,25(OH)2D reduces 
insulin sensitivity in 3T3-L1 adipocytes. Data are expressed as fold increase in 2-
deoxyglucose uptake with acute insulin stimulation, and are normalized to total 











Figure 3.13. Effect of 1,25(OH)2D on glucose transporter mRNA expression. 
Differentiated 3T3-L1 adipocytes were treated with vehicle or 1,25(OH)2D (10 
nM) for 4 days. GLUT1 and GLUT4 mRNA are expressed relative to vehicle. 




Figure 3.14. 1,25(OH)2D does not affect glucose consumption or lactate 
secretion in 3T3-L1 adipocytes.  Differentiated 3T3-L1 adipocytes were treated 
with vehicle or 1,25(OH)2D (10 nM) for 1-4 days as indicated.  Glucose 
concentrations were assessed in spent media samples using a commercially 
available kit. Glucose consumption was calculated from the difference between 
glucose concentrations in spent and in fresh media samples. Data are expressed 
as nmol•min-1•mg protein-1, and are normalized to total protein.  No effect of 











Figure 3.15. 1,25(OH)2D reduces pyruvate carboxylase mRNA expression in 
3T3-L1 adipocytes.  Differentiated 3T3-L1 adipocytes were treated with vehicle or 
1,25(OH)2D (10 nM) for 2 days.  The mRNA expression of pyruvate carboxylase 











Figure 3.16. Human PC mRNA abundance with PC overexpression.  
Differentiated 3T3-L1 adipocytes were transfected with a plasmid containing the 
human PC gene as described in Materials and Methods. The mRNA expression 









Figure 3.17. Overexpression of pyruvate carboxylase increases glucose 
incorporation into fatty acids.  Differentiated 3T3-L1 adipocytes were transfected 
as described in Materials and Methods. 24 hours following transfection with the 
PC or control plasmid, cells were stimulated with 1,25(OH)2D (10 nM) or vehicle 
for 4 days. Cells were incubated with D-[U-13C]glucose during the last 48 hours of 
treatment as described in Materials and Methods, and substrate incorporation 
into the cellular pool of palmitic, palmitoleic, stearic, and oleic acids was 
assessed using HPLC/ESI-MS/MS. Data are as the percent of labeled fatty acids 




Figure 3.18. Overexpression of pyruvate carboxylase reduces glycerol and 
lactate secretion.  Differentiated 3T3-L1 adipocytes were transfected as 
described in Materials and Methods. 24 hours following transfection with the PC 
or control plasmid, cells were stimulated with 1,25(OH)2D (10 nM) or vehicle for 2 
days. Glycerol (A) and lactate (B) release were assessed in spent media 
samples as described in Materials and Methods. Bars with different letters are 




Figure 3.19. Inhibition of glycolysis blunts 1,25(OH)2D-stimulation of glycerol 
release in 3T3-L1 adipocytes.  Differentiated 3T3-L1 adipocytes were co-treated 
with 1,25(OH)2D (10 nM) and 2-deoxyglucose (20 mM) for 2 days.  Glycerol 
release was assessed in spent media samples by quantitative enzymatic 
determination of free glycerol using a commercially available kit. *P<0.05 




CHAPTER 4. DISCUSSION 
 As the prevalence of obesity across age, ethnic, and socioeconomic 
groups increase, so does the need to identify safe and effective measures by 
which we can prevent and reverse the disease. Both hypertrophy (increase in cell 
size) and hyperplasia (increase in cell number) have been targeted as pathways 
that might be modulated in an attempt to ameliorate the progression of obesity 
and associated metabolic disorders. While both of these pathways contribute to 
the maintenance of white adipose tissue, a study by Spalding et al. demonstrate 
that changes in fat mass, even in cases of significant weight gain or loss, are due 
to changes in adipocyte size rather than alterations in adipose cell number (105). 
In this study, Spalding et al. observed an annual adipocyte turnover rate of 10%, 
independent of age and BMI, yielding an average adipocyte lifespan of 
approximately 10 years. These data highlight the significance that regulation of 
lipid accumulation in existing adipocytes plays in the modulation of adipose 
mass.  
 Observation of the inverse relationship between vitamin D status and 
measures of adiposity in humans has triggered a high level of interest in the 
relationship between vitamin D and obesity. Many studies have been conducted 
to determine the impact of vitamin D on adipogenesis, or differentiation of 
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adipocytes; however, there is little knowledge of the impact of vitamin D on lipid 
storage and metabolism in differentiated adipocytes. In the present studies, 
1,25(OH)2D stimulated a significant reduction in TAG accumulation in 
differentiated 3T3-L1 adipocytes. We demonstrate that mitochondrial β-oxidation 
is stimulated by 1,25(OH)2D in these adipocytes, and the data suggest that 
1,25(OH)2D stimulates a reduction in the utilization of glucose for fatty acid 
synthesis, while increasing glucose utilization for the synthesis and secretion of 
glycerol. To our knowledge, these results are the first to demonstrate directly that 
1,25(OH)2D alters fatty acid synthesis and oxidation in differentiated adipocytes. 
 It is well-established that vitamin D is stored in adipose tissue, and as a 
result, many studies have been performed to determine the impact of vitamin D 
on adipogenesis, or hyperplasia. Studies utilizing the 3T3-L1 preadipocyte cell 
line found that 1,25(OH)2D inhibits differentiation of these cells, and subsequent 
lipid accumulation, by downregulating differentiation “master regulator” PPARγ 
and C/EBPα (205-208). Downregulation of these genes inhibits the subsequent 
expression of genes necessary for lipid and glucose metabolism, and 
consequently, preservation of the preadipocyte phenotype. However, the impact 
of vitamin D on adipocyte differentiation remains controversial. While 1,25(OH)2D 
inhibits the differentiation of murine 3T3-L1 adipocytes, 1,25(OH)2D stimulates 
maturation and lipid accumulation during the adipogenic differentiation of porcine 
mesenchymal stem cells (212) and human subcutaneous preadipocytes (213). 
The discrepancy between these different cell lines, while not fully understood, 
may be attributed to the different roles that adipose tissue plays with regard to 
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energy balance in these species, or due to the stage of differentiation that 
isolated human subcutaneous adipocytes are in compared to the 3T3-L1 
preadipocyte cell line.  
 Reports of vitamin D regulation of lipid metabolism and accumulation in 
differentiated adipocytes are limited. One study performed by Zoico et al. (248) 
examined the impact 1,25(OH)2D on the lipopolysaccharide (LPS)- induced 
inflammatory response in 3T3-L1 adipocytes that had been differentiated for 5 
days. In this study, stimulation with LPS (1.0 µg/mL) for 24 hours triggered a 
significant increase in the secretion of pro-inflammatory adipokines IL-6 and 
TNFα, with a concomitant increase in lipid accumulation, measured by Oil Red-O 
staining. However, when differentiated 3T3-L1 adipocytes were pre-treated with 
1,25(OH)2D (100 nM) for 24 hours, the LPS-induced increases in cytokine 
secretion and lipid accumulation were attenuated. These data suggest a role for 
vitamin D in the regulation of inflammation-mediated lipid metabolism; however, 
no impact of 1,25(OH)2D was observed on lipid accumulation in the absence of 
LPS-induced inflammation. 
 In contrast to the null results described by Zoico et al. with regard to the 
impact of 1,25(OH)2D on lipid accumulation in a non-inflammatory state, a recent 
study published by Chang and Kim documented a reduction in lipid accumulation 
in 3T3-L1 adipocytes with 1,25(OH)2D stimulation (249). In these studies, 3T3-L1 
adipocytes that had been differentiated for 6 or 7 days were stimulated for 24 
hours with 1-100 nM 1,25(OH)2D (249). An approximate 15% reduction in lipid 
accumulation, measured by Oil Red O staining, was observed following 24 hours 
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of 1 nM 1,25(OH)2D stimulation, with similar reductions in lipid accumulation 
occurring with 10 and 100 nM 1,25(OH)2D treatment. Consistent with the studies 
described in this dissertation, Chang and Kim observed a significant increase in 
basal glycerol release with 24 hours of 1,25(OH)2D treatment, and the authors 
report 1,25(OH)2D enhancement of isoproterenol-induced glycerol release. 
Further, the mRNA expression of lipogenic genes (C/EBPα, FAS, PPARγ, SCD-
1) were significantly reduced by 1,25(OH)2D, while lipid oxidizing genes (CPT-1, 
PGC-1α, PPARα, UCP-1) were significantly increased following 1,25(OH)2D 
stimulation.  These 1,25(OH)2D-induced changes in lipid accumulation and lipid 
metabolizing gene expression occurred with a concomitant increase in sirtuin-1 
(SIRT1) mRNA expression and activity. SIRT1 promotes fatty acid mobilization 
from adipose tissue (250), and these data suggest that 1,25(OH)2D may reduce 
lipid accumulation in 3T3-L1 adipocytes by activating this metabolic pathway. 
However, 1,25(OH)2D regulation of adipocyte lipid accumulation remains far from 
fully understood. 
 While the studies described by Chang and Kim provide some insight into 
the actions of 1,25(OH)2D in adipocytes, the role of 1,25(OH)2D in regulating 
adipose function and pathophysiology remain incompletely defined. The authors 
report an increase in NAD/NADH ratio and SIRT1 activity with 1,25(OH)2D 
treatment (249). SIRT1 acts as a metabolic sensor, acting in coordination with 
AMPK to increase oxidative capacity in tissues such as skeletal muscle (251), 
and promote lipid mobilization from adipose tissue to support fatty acid oxidation 
in peripheral tissues (250). As AMPK is known to activate SIRT1 by increasing 
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the NAD/NADH ratio (252), it would have been interesting to know if 1,25(OH)2D 
stimulates activation of AMPK in these cells as well. Further, given the extensive 
history of discrepancies between 1,25(OH)2D action in vitro and the impact of 
dietary vitamin D on adipose tissue in vivo (215), it would have been valuable if 
functional outcomes such as fatty acid oxidation and fatty acid synthesis had 
been measured in these studies directly, rather than relying on the mRNA 
expression of genes related to FA metabolism alone to determine the impact of 
1,25(OH)2D on adipose tissue physiology.  
 As the available evidence regarding the impact of vitamin D on 
differentiated adipocytes remains limited, the collective aim of the present studies 
was to determine the impact of 1,25(OH)2D on lipid metabolism and storage in 
3T3-L1 adipocytes. In these studies, we observed a 21% reduction in TAG 
accumulation after 4 days of stimulation with 10 nM 1,25(OH)2D (Figure 3.1). 
This reduction in TAG accumulation persisted for up to 7 days, and was achieved 
without negatively impacting cell viability (Figure 3.2). In addition to the reduction 
in TAG accumulation, we found that 1,25(OH)2D stimulates glycerol release after 
1-4 days, with a maximal increase in glycerol release following 48 hours of 
treatment (Figure 3.3). These data are consistent with the recently published 
study by Chang and Kim, who demonstrate a significant increase in glycerol 
release and reduction in lipid accumulation following 24 hours of 10 nM 
1,25(OH)2D treatment (249).  
 Typically, glycerol release is indicative of lipolysis. However, while several 
changes in the lipolysis signaling pathway were observed in response to 
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1,25(OH)2D, collectively, the data obtained from the current studies do not 
suggest that 1,25(OH)2D stimulates TAG hydrolysis. Consistent with TAG 
hydrolysis, 1,25(OH)2D-induced glycerol release is abolished upon chemical 
inhibition of PKA (Figure 3.5A). Further, 1,25(OH)2D stimulates increased 
phosphorylation of HSL at PKA phosphorylation site Ser660 (Figure 3.5B), and 
interestingly, an increase and decrease in ATGL and CGI-58 protein expression, 
respectively (Figure 3.5C).  Previous studies have demonstrated that retroviral-
mediated overexpression of ATGL increases basal glycerol and NEFA release in 
3T3-L1 adipocytes, while siRNA-mediated knockdown of ATGL has the opposite 
effect (253). Given the increase in basal glycerol release by 1,25(OH)2D, 
downregulation of ATGL protein expression is contrary to what might be 
expected. However, ATGL requires activation by CGI-58 to hydrolyze TAG, and it 
has been demonstrated that the molar ratio of CGI-58:ATGL is positively 
associated with ATGL hydrolase activity (85). Therefore, the increase in CGI-58 
protein expression in concert with downregulation of ATGL protein expression 
results in an elevated CGI-58:ATGL molar ratio, and consequently, is consistent 
with elevated glycerol release. 
 While these changes in the lipolysis signaling pathway suggest that 
1,25(OH)2D may stimulate glycerol release by hydrolyzing TAG, not all data are 
consistent with this hypothesis. First, the reduction in TAG accumulation that is 
achieved following 4 days of 1,25(OH)2D treatment (-0.514 µmols, based on an 
average TAG mw of 846.09 g/mol) does not quantitatively account for the 
increase in the number of moles of glycerol that are secreted following 1-4 days 
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of 1,25(OH)2D stimulation (+29.68 µmols). Further, while glycerol release is 
typically indicative of lipolysis, as complete TAG hydrolysis yields NEFA and 
glycerol moieties in a 3:1 molar ratio, no increase in NEFA release was observed 
with 1,25(OH)2D (data not shown). Finally, intracellular cAMP levels, which 
become elevated in response to lipolytic stimuli in order to activate PKA, were 
not changed following 1,25(OH)2D treatment (Figure 3.6). These data suggest 
that 1,25(OH)2D may stimulate stimulates glycerol synthesis from glycolytic or 
glyceroneogenic precursors, rather than hydrolysis of TAG. Previous studies 
have demonstrated that adipocytes dispose of glucose as glycerol, particularly in 
response to high glucose concentrations (95) such as the standard culture 
medium used in these studies. 
 To test the hypothesis that 1,25(OH)2D stimulates synthesis of glycerol 
from glycolytic/glyceroneogenic precursors, adipocytes were co-treated with 
1,25(OH)2D and 2-deoxyglucose, a known inhibitor of glycolysis. Inhibition of 
glycolysis completely prevented 1,25(OH)2D stimulation of glycerol release in 
3T3-L1 adipocytes (Figure 3.19). Since lactate, the primary substrate for 
glyceroneogenesis in adipocytes, is produced from pyruvate obtained through 
glycolysis, this assay is not capable of distinguishing between glycerol produced 
from non-glucose precursors (glyceroneogenesis) or directly from glucose 
(glycolysis). However, these data do suggest that 1,25(OH)2D stimulates 
synthesis of glycerol via one of these pathways, rather than hydrolysis of TAG. 
These data also highlight the possibility of altered glucose metabolism in 
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response to 1,25(OH)2D, and the potential contribution of de novo lipogenesis to 
the 1,25(OH)2D-induced reduction in TAG accumulation. 
 In the current studies, 1,25(OH)2D reduced glucose incorporation into fatty 
acids by 30% compared to vehicle-treated cells (Figure 3.9), without altering the 
rate of glucose consumption (Figure 3.14A). To determine whether the reduction 
in glucose incorporation into fatty acids was a consequence of an impaired ability 
to synthesize fatty acids, in separate experiments, acetate incorporation into fatty 
acids was also measured. Acetate incorporation into fatty acids, a measure of 
fatty acid synthesis, was reduced by only 10% in response to 1,25(OH)2D (Figure 
3.10). These data suggest that while fatty acid synthesis is slightly inhibited in 
response to 1,25(OH)2D, possibly via reduced enzymatic activity of fatty acid 
synthase and/or acetyl-CoA carboxylase, 1,25(OH)2D stimulates a reduction in 
the utilization of glucose specifically for the synthesis of fatty acids. As glucose 
consumption (Figure 3.14A) and lactate secretion (Figure 3.14B) were not 
impacted following 1-4 days of treatment, the reduction of glucose incorporation 
into fatty acids is consistent with adipocytes disposing of excess glucose as 
glycerol. The possibility that 1,25(OH)2D stimulates glucose disposal as glycerol 
as a consequence of reduced glucose flux into the TCA cycle was explored. 
As 1,25(OH)2D reduced the utilization of glucose for fatty acid synthesis, it 
is possible that 1,25(OH)2D reduces flux of glucose into the TCA cycle. By 
entering into the TCA cycle, glucose-derived pyruvate serves as a source of 
ATP. Additionally, by replenishing TCA cycle intermediates, pyruvate supplies 
carbon substrate in the form of acetyl-CoA for fatty acid synthesis. Previous 
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studies by our laboratory demonstrate that 1,25(OH)2D reduces pyruvate 
carboxylase expression and enzymatic activity in human breast epithelial cells, 
leading to reduced glycolysis and glucose flux into the TCA cycle (unpublished 
data). Consistent with these studies, results from the current studies demonstrate 
that 1,25(OH)2D reduces PC mRNA expression in 3T3-L1 adipocytes (Figure 
3.15). To determine whether 1,25(OH)2D reduces glucose utilization as a 
substrate for fatty acid synthesis, and consequently TAG accumulation, by 
reducing pyruvate carboxylase activity, human PC (hPC) was overexpressed in 
differentiated 3T3-L1 adipocytes. Despite a 6.5-fold increase in PC mRNA 
expression, PC overexpression failed to inhibit 1,25(OH)2D-induced changes in 
glycerol release (Figure 3.18A) and glucose incorporation into fatty acids (Figure 
3.17), suggesting that PC does not mediate the 1,25(OH)2D-induced changes in 
fatty acid synthesis and accumulation. Whether 1,25(OH)2D stimulates reduced 
glucose flux into the TCA cycle remains to be determined. Collectively, the 
available data do suggest that 1,25(OH)2D does stimulate glucose disposal as 
glycerol. 
 The impact of elevated glycerol release may have implications in hepatic 
gluconeogenesis and systemic glucose homeostasis. Glycerol and lactate are 
the major substrates for hepatic gluconeogenesis, and under fasted conditions, 
glycerol release from adipocytes by lipolysis is a major contributor to hepatic 
glucose synthesis (254). Previous studies have demonstrated that glycerol 
delivery to the liver can stimulate hepatic glucose production by a substrate-
dependent push mechanism, independent of insulin signaling (255-257). Since 
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hepatic gluconeogenesis is a major contributor to the hyperglycemia that is 
observed in type 2 diabetes (258), this raises the concern about the impact of 
1,25(OH)2D-stimulated glycerol release in adipocytes in vivo. However, many 
cross-sectional studies have reported a positive relationship between vitamin D 
status and insulin sensitivity (259), as well as a positive impact of vitamin D on 
hepatic glucose and lipid metabolism (260). While overall the existing evidence 
does not support that vitamin D supplementation improves insulin sensitivity in an 
insulin-resistance state (187), the available evidence does suggest that it unlikely 
that vitamin D action in adipocytes disrupts global glucose homeostasis in 
humans. 
 In the current studies, FA oxidation was increased approximately 2.5-fold 
by 1,25(OH)2D in 3T3-L1 adipocytes (Figure 3.8A). This is, to our knowledge, the 
first report of increased fatty acid oxidation in response to 1,25(OH)2D in white 
adipocytes. While no reports of vitamin D stimulation of fatty acid oxidation in 
white adipocytes have been made, a few studies have documented evidence that 
vitamin D may play a role in fatty acid oxidation in other tissues, and contribute 
positively to the maintenance of energy homeostasis. A study by Marcotorchino 
et al. examined the effect of dietary vitamin D on high fat diet-induced weight 
gain and glucose homeostasis in C57BL/6 mice (261). In this study, despite no 
difference in energy intake between mice given a high fat diet with standard 
vitamin D (1,500 IU/kg food, HF) and those given a high fat diet with high vitamin 
D (15,000 IU/kg food, HFVD), HFVD mice gained significantly less body and 
adipose mass than HF mice after 10 weeks. The authors found that HFVD mice 
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had a significantly lower respiratory quotient, and increased energy expenditure 
and lipid oxidation compared to HF mice, reflecting the preferential use of lipids 
vs. carbohydrates as an energy source. Gene expression of enzymes related to 
fatty acid oxidation were elevated in BAT, liver, and skeletal muscle of HFVD 
compared to HF mice. While fatty acid oxidation was not examined in white 
adipose tissue specifically, these data do demonstrate the ability of vitamin D to 
increase global energy expenditure, and consequently, protect against excessive 
accumulation of adipose tissue. The data obtained by Marcotorchino et al. and 
those described from the current studies both provide mechanistic support for the 
inverse relationship between vitamin D and obesity.   
 In addition to the global impact of dietary vitamin D on fatty acid oxidation 
described above, vitamin D has been reported to increase FAO and reduce FA 
synthesis specifically in hepatocytes (262). In this study, male Sprague-Dawley 
rats were fed a control diet, or a high fat diet plus intraperitoneal injection of 1, 
2.5, or 5 µg/kg 1,25(OH)2D. Administration of 1,25(OH)2D ameliorated HF diet-
induced body and liver weight gain, increased the hepatic mRNA expression of 
FAO-related genes (PPARα and CPT-1), and reduced the hepatic mRNA 
expression of genes involved in lipogenesis (SREBP-1c, ACC, FAS). These data 
suggest that 1,25(OH)2D protects against hepatic steatosis by stimulating FAO, 
while inhibiting lipogenesis in the liver. Again, these data highlight the role of 
vitamin D in the regulation of energy expenditure and lipid homeostasis, and 
provide mechanistic support of the inverse relationship between vitamin D and 
obesity. However, it must be noted that the studies described by Marcotorchino 
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et al. (261) and Yin et al. (262) examined only the impact of vitamin D (dietary or 
intraperitoneal injection of 1,25(OH)2D, respectively) on high fat diet-induced 
weight gain and metabolism, without including a control group to examine the 
impact of vitamin D on energy and lipid metabolism in the non-obese state. Such 
studies are essential in order to fully understand the impact of vitamin D on lipid 
oxidation and metabolism. 
 The studies described above demonstrate that vitamin D may impact lipid 
oxidation in oxidative tissues such as the liver, skeletal muscle, and BAT. 
However, very limited data exist regarding the impact of fatty acid oxidation in 
WAT. While β-oxidation is most well-studied in these oxidative tissues, oxidative 
capacity in adipocytes is reduced during obesity and in the diabetic state (263, 
264), and targeting oxidative metabolism in WAT is an effective treatment 
measure in type 2 diabetes (265, 266). Consistent with our observation of 
increased β-oxidation with 1,25(OH)2D stimulation, the recent report by Chang 
and Kim demonstrates that 1,25(OH)2D stimulates the mRNA expression of 
several genes related to fatty acid oxidation in 3T3-L1 adipocytes, including CPT-
1α, PGC1α, UCP-1, and PPARα, providing additional support that vitamin D may 
increases FAO in these cells (249).  
 This increase in fatty acid oxidation that was observed in the present 
studies is interesting, given the reduction in CPT-1 mRNA expression, and 
increase in ACC1 mRNA expression, in response to 1,25(OH)2D (Figure 3.8B). 
Flux of the β-oxidation pathway is determined primarily by CPT-1 (267, 268) and 
by substrate supply (267, 269). When cellular energy stores are low, AMPK 
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phosphorylates ACC, thereby inactivating it (270). This phosphorylation event 
inhibits ACC-mediated production of malonyl-CoA, a potent CPT-1 inhibitor, 
allowing ATP-yielding processes such as β-oxidation to occur, while limiting ATP-
consuming processes such as de novo lipogenesis. Conversely, during times of 
adequate cellular energy states, ACC1 remains in its active, unphosphorylated 
state, producing malonyl-CoA for the synthesis of fatty acids, and inhibiting the 
ATP-producing process of β-oxidation. As ACC1 is regulated primarily by 
phosphorylation rather than transcriptionally, its mRNA levels in the cell may not 
necessarily reflect its enzymatic activity. These findings are significant, given that 
many of the previously described studies of 1,25(OH)2D action on adipocytes 
report only changes in the mRNA expression of lipogenic and oxidative enzymes, 
without examining enzyme functionality or activity. For example, the impact of 
1,25(OH)2D on CPT-1 expression described herein is in contrast to the findings 
described by Chang and Kim, who report a significant increase in CPT-1 mRNA 
expression in 3T3-L1 adipocytes in response to 1,25(OH)2D (249). Nonetheless, 
the data from both the current studies and those described by Chang and Kim 
are consistent with 1,25(OH)2D stimulation of fatty acid oxidation in differentiated 
3T3-L1 adipocytes.  
 To determine if 1,25(OH)2D reduces TAG accumulation in 3T3-L1 
adipocytes by inhibiting the uptake of exogenous fatty acids, the impact of 
1,25(OH)2D on uptake of the fluorescent C16 BODIPY fatty acid was observed. 
Despite the observed reduction in TAG accumulation, uptake of the C16 BODIPY 
fatty acid was elevated in response to 1,25(OH)2D (Figure 3.7). These data 
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suggest that 1,25(OH)2D enhances the adipocyte’s ability to take up exogenous 
fatty acids. However, under the experimental conditions used for these studies, 
the contribution of exogenous fatty acids to the intracellular TAG pool remains 
limited. In these experiments, exogenous fatty acids were not directly supplied 
during or after differentiation. Rather, the contribution of exogenous lipids to the 
intracellular TAG pool was limited to the amount of fatty acids that were present 
in the cell culture sera, supplied in the culturing media in a 10% (vol:vol) ratio. In 
an environment where exogenous fatty acids are more freely or frequently 
available, such as those found in circulation in vivo postprandially, the 
contribution of exogenous lipids to intracellular TAG pool may be significantly 
larger, and may impact the overall effect of 1,25(OH)2D on TAG accumulation in 
vivo.  
It is established that long-chain fatty acids (LCFA) stimulate FAO by acting 
as PPAR ligands, stimulating the transcription of lipid-oxidizing genes (271). As 
1,25(OH)2D stimulates uptake of BODIPY FL16 in 3T3-L1 adipocytes, the 
possibility that FAO is increased indirectly by 1,25(OH)2D, as a result of 
increased uptake of 1-14C-palmitate, was raised. To address this question, 
uptake of 1-14C-palmitate was determined under conditions used for the FAO 
assay. Under these conditions, uptake of 1-14C-palmitate is not different between 
vehicle- and 1,25(OH)2D-treated cells (Figure 3.8C). The discrepancy between 
uptake of BODIPY fatty acid and 1-14C-palmitate may be due to the difference in 
substrate concentration used in each of these assays. As fatty acid uptake 
occurs via both diffusion and protein-mediated uptake (71), it is likely that at low 
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substrate concentrations, such as those used for the BODIPY FA uptake assay, 
differences in protein mediated uptake may be observed. Conversely, under 
conditions of high substrate availability, protein-mediated and passive diffusion of 
fatty acids across the cell membrane are maximized, and differences in protein-
mediated uptake may not be detected. Since no difference in 1-14C-palmitate 
uptake was observed between vehicle- and 1,25(OH)2D-treated cells, it is 
unlikely that indirect stimulation of FAO by increased FA uptake is the 
mechanism by which 1,25(OH)2D stimulates FAO in these cells.  
The data from these studies demonstrate that 1,25(OH)2D acts in 
differentiated adipocytes to regulate lipid and glucose metabolism, leading to 
reduced TAG accumulation. While the impact of vitamin D supplementation on 
weight loss remains controversial (272), these data provide mechanistic support 
for the inverse relationship between vitamin D status and measures of adiposity. 
However, studies to determine the clinical significance of these findings are 
needed. Many in vitro studies have been performed to determine the impact of 
vitamin D on adipose tissue physiology, specifically, on adipocyte differentiation, 
but the impact of 1,25(OH)2D on adipogenesis in humans is still unclear. 
1,25(OH)2D inhibits adipogenesis in murine 3T3-L1 preadipocytes, while 
promoting differentiation in human preadipocytes and primary mouse adipocytes 
at an advanced stage of differentiation (272). These data suggest that the impact 
of 1,25(OH)2D on adipogenesis is dependent on stage of differentiation. On the 
other hand, while limited in quantity and restricted to the 3T3-L1 cell line, the 
available evidence regarding 1,25(OH)2D regulation of already differentiated 
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adipocytes consistently demonstrate that 1,25(OH)2D reduces lipid accumulation 
in these cells, at least in part by regulating metabolic pathways that are 
independent of the signaling pathways that control early adipogenesis. Whether 
1,25(OH)2D has the same impact on differentiated human adipocytes remains to 
be determined. 
That 1,25(OH)2D modulates adipocyte metabolism and lipid storage 
independently from its effects on the adipogenic program highlights the potential 
for vitamin D to impact adipose tissue physiology through its effects on existing 
adipocytes, in addition to its potential effects on differentiation of preadipocytes 
and mesenchymal stem cells. This may have therapeutic potential, as significant 
changes in adipose mass are mainly due to alterations in cell size rather than cell 
number (105). It has been demonstrated that adipocyte size is positively 
correlated with serum insulin and leptin concentrations, insulin resistance, and 
risk of developing type 2 diabetes (273-281).  Obese individuals with few, large 
adipocytes are more glucose intolerant and hyperinsulinemic than those having 
the same degree of adiposity but in many small adipocytes (276-278, 282). 
Further, large adipocyte size may impair adipose function by promoting local 
inflammation and altered adipokine secretion (283-287). These data suggest that 
for a given state of adiposity, a higher number of smaller adipocytes is more 
metabolically favorable than fewer, larger adipocytes.  
Given that it is more metabolically favorable to distribute adipose mass 
over a larger number of smaller adipocytes, agents such as 1,25(OH)2D that 
reduce adipocyte size by reducing accumulation in existing (differentiated) 
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adipocytes, or possibly by distributing the existing fat mass over a larger number 
of adipocytes through stimulation of adipogenesis, may be beneficial in 
preserving metabolic function. In support of this, a study by Caron-John et al. 
demonstrated that in women undergoing abdominal gynecological surgery, intake 
of vitamin D was inversely correlated with omental adipocyte size, independent of 
calcium intake, BMI, total body fat mass, season, and physical activity.(288). In 
this study, Serum 25(OH)D was also negatively correlated with omental 
adipocyte size, and with total fat mass. Dietary intakes of vitamin D, calcium, and 
dairy products were assessed using a food frequency questionnaire, and mean 
adipocyte size was calculated by measuring the diameter of 250 adipocytes per 
patient. These data provide support for vitamin D regulation of adipose tissue 
physiology in humans, and highlight a potential mechanism by which dietary 
vitamin D may protect against obesity-associated metabolic disorders.  
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CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS 
5.1 Conclusions  
In conclusion, 1,25(OH)2D impacts several processes related to fatty acid 
and glucose metabolism in differentiated 3T3-L1 adipocytes, leading to reduced 
TAG accumulation. 1,25(OH)2D stimulates glycerol release, likely due to 
stimulation of glycerol synthesis from glucose-derived substrates (e.g. during 
glycolysis, or from lactate or pyruvate). Fatty acid uptake and oxidation are 
stimulated by 1,25(OH)2D, while glucose utilization as a substrate for fatty acid 
synthesis is reduced. Collectively, these changes in adipocyte metabolism may 
contribute to the reduction in TAG accumulation that is stimulated by 1,25(OH)2D. 
The results of this study may aid in the identification of metabolic pathways 
targeted by 1,25(OH)2D, and in the development of in vivo studies designed to 
examine the impact of dietary vitamin D on obesity and related metabolic 
disorders.  
5.2 Future Directions 
While the studies described herein improve our understanding of vitamin D 
regulation of adipose tissue metabolism, several questions remain regarding 
vitamin D impact on adipose tissue metabolism and function.  
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First, the studies described in this dissertation utilized the murine 3T3-L1 
preadipocyte cell line to examine the impact of 1,25(OH)2D on glucose and lipid 
metabolism and TAG accumulation in adipocytes. Given the discrepancies in 
1,25(OH)2D action on preadipocyte differentiation between mouse and human 
preadipocytes, it will be essential to examine the impact of 1,25(OH)2D on energy 
substrate metabolism and TAG accumulation in differentiated human adipocytes. 
The discrepancy in 1,25(OH)2D action between mouse and human preadipocytes 
may be due to differing actions of 1,25(OH)2D on the adipogenic transcriptional 
cascade, and may be dependent on the stage of differentiation that the cell is in. 
Therefore, the impact of 1,25(OH)2D on human adipocyte metabolism after the 
differentiation program is complete will need to be studied directly. This 
knowledge is key in understanding the vitamin D regulation of adipose tissue in 
humans. 
Second, it will be useful to determine the minimum concentration of 
1,25(OH)2D necessary to elicit changes in glucose and lipid metabolism, and in 
TAG accumulation in adipocytes. The concentration of 1,25(OH)2D used in the 
current studies (10 nM) was chosen in order to ensure the ability to capture the 
cellular response to 1,25(OH)2D stimulation. While adipose tissue concentrations 
of 1,25(OH)2D and rate of local adipose production of 1,25(OH)2D are not known, 
serum 1,25(OH)2D concentrations are generally in the picomolar range. Chang 
and Lee demonstrated that 1,25(OH)2D reduces neutral lipid accumulation in 
concentrations as low as 1 nM (249), suggesting that the 1,25(OH)2D-induced 
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changes in glucose and lipid metabolism may also occur at lower 1,25(OH)2D 
concentrations.  
Finally, the impact of dietary vitamin D on adipocyte metabolism and 
substrate handling must be examined in vivo. A study designed to examine: 1) 
whether dietary vitamin D may elicit changes in adipose tissue metabolism and 
total fat mass that are consistent with the current in vitro studies (e.g. elevated 
glycerol release and fatty acid oxidation in adipose tissue); and 2) the impact of 
altered adipose metabolism on systemic energy balance, lipid profile, and 
glucose homeostasis. It is possible that chronically elevated glycerol supplied to 
the liver by adipose tissue would stimulate gluconeogenesis leading to elevated 
fasting blood glucose. However, this scenario is unlikely, given the positive 
association between vitamin D status and insulin sensitivity (259), and the 
favorable impact of high dietary vitamin D on liver glucose and lipid metabolism 
(260). While several questions remain to be answered, the studies described in 
this dissertation provide information that is critical to improve our understanding 
of the actions of 1,25(OH)2D on adipose tissue metabolism and function, and that 
provides mechanistic support for the inverse relationship between vitamin D 
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